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    SYNOPSIS
1The work is incorporated in the thesis with the title “STUDIES ON CHEMICAL
ENTITIES OF THERAPEUTIC INTEREST” has been described as under.
STUDIES ON CHALCONE DERIVATIVES
The chemistry of chalcones containing an active keto-ethylenic linkage has
assumed importance because of their versatility in the synthesis of many heterocyclic
compounds. Furthermore, they are also associated with wide spectrum of pharma-
cological activities and industrial applications. The chalcones are reported to pos-
sess antibacterial, antiviral, agrochemical and diuretic activities. They have been found
to be applicable for photosensitive materials, polymerization catalysts fluorescents
brightening agents, pigments etc. With a view to supplement these valid observa-
tions, it was contemplated to synthesize some novel chalcone derivatives using 1-(4-
methanesulfonyl-phenyl)-ethanone with better biological activities which have been
described as under.
PART - I    :   STUDIES ON  PYRAZOLINES
Pyrazoline derivatives are endowed with different therapeutic activities such
as antibacterial, analgesic, anthelmintic, antiinflammatory, antitubercular etc. These
valid observations led us to synthesize some novel pyrazoline derivatives bearing
methylsulfonyl  moiety, which have been described as under.
SECTION-I : Synthesis and biological evaluation of 1-[4-(Methyl
sulfonyl)phenyl]-3-aryl-2-propene-1-ones







2The chalcone derivatives of Type (I) have been synthesized by the
reaction of 1-[4-(methylsulfonyl)phenyl]-ethanone with different  aryl aldehyde in
presence of 40% NaOH.
SECTION -II : Synthesis and biological evaluation of 1-Acetyl-3-[4-
(methylsulfonyl)phenyl]-5-aryl-4,5-dihydro-1H-pyrazoles
The pyrazoline derivatives of Type(II) have been synthesized by the
condensation of the chalcones of Type(I) with hydrazine hydrate in glacial acetic
acid.
SECTION - III: Synthesis and biological evaluation of 3-[4-(Methyl
sulfonyl)phenyl]-5-aryl-4,5-dihydro-1H-pyrazoles
The synthesis of pyrazoline derivatives of Type(III) have been undertaken by
the cyclocondensation of the chalcones of Type(I) with  hydrazine hydrate.














3PART - II    :   STUDIES ON  CYANOPYRIDINES
Cyanopyridine derivatives have attracted considerable attention in view of
their great therapeutic importance as anticonvulsant, antifungal, antibacterial,
antidiabetic and hypertensive agents. In order to developing therapeutically  importnat
compounds, it was considered of interest to synthesize some new canopyridine de-
rivatives shown as under.
SECTION-I : Synthesis and biological evaluation of 2-Methoxy-6-[4-
(methylsulfonyl)phenyl]-4-arylnicotinonitriles
Cyanopyridine derivatives of Type(IV) have been prepared by the
reaction of chalcones of Type(I) with malononitrile and sodium methoxide.
PART - III    :   STUDIES ON  CYANOPYRIDONES
Cyanopyridone derivatives are endowed with different therapeutic activities
such as antibacterial, analgesic, anthelmintic, antiinflammatory, antitubercular etc.
These valid observations led us to synthesize some new cyanopyridone derivatives
bearing  m ethylsulfonyl  moiety, which have been described as under.
SECTION - I: Synthesis and biological evaluation of 6-[4-(Methyl
sulfonyl)phenyl]-2-oxo-4-aryl-1,2dihydropyridine-3-
carbonitriles







4 Cyanopyridone derivatives of Type(V) have been prepared by the
reaction of chalcones of Type (I) with ethyl cyano acetate in presence of basic
catalyst like pyridine.
PART - IV    :   STUDIES ON CYANOPYRANS
Cyanopyran derivatives exhibit various interesting biological properties such
as antimicrobial, antifungal, antiviral, antifilarial and antisecretory. In view of these
facts,  it was contemplated to synthesized  some new pyrans, which have been
described as under.
SECTION-I : Synthesis and biological evaluation of 2-Amino-6-[4-
(methylsulfonyl)phenyl]-4-aryl-4H-pyran-3-carbonitriles
Cyanopyran derivatives of Type (VI) have been prepared by the reaction of
chalcones of Type (I) with malononitrile in pyridine.
Type (V) R = Aryl














5PART - V    :   STUDIES ON PYRIMIDINES
Pyrimidine nucleus possess remarkable pharmaceutical importance  and
biological activities, some of their derivatives occur as natural product, like nucleic
acids and vitamin B. Pyrimidine derivatives used for the treatment of AIDS and as
antitumor agents,  These valid observations led us to synthesize some novel
pyrimidine in search of agents having more medicinally activities which have been
described as under.
SECTION - I: Synthesis and biological evaluation of 4-[4-(Methyl
sulfonyl)phenyl]-6-arylpyrimidin-2(1H)-ones
Pyrimidinone derivatives of Type (VII) have been prepared by the
condensation of chalcones of Type (I) with urea  in presence of acidic catalyst like
HCl.
SECTION-II : Synthesis and biological evaluation of 4-[4-(Methyl
sulfonyl)phenyl]-6-arylpyrimidin-2(1H)-thiones















Type (VIII) R = Aryl
6Pyrimidine thione derivatives of Type (VIII) have been prepared by the
condensation of chalcones of Type(I) with thiourea  in presence of acidic catalyst
like HCl.
SECTION-III : Synthesis and biological evaluation of 4-[4-(Methyl
sulfonyl)phenyl]-6-arylpyrimidin-2-amines
Aminopyrimidine derivatives of Type (IX) have been synthesized by the
condensation of chalcones of Type (I) with guanidine hydrochloride.
PART - VI    :   STUDIES ON INDAZOLES
 Biological importance of indazole derivatives is well known. They have been
reported to be active as cardiovasscular, sedative, antifungal and antibecterial. In
order to develop medicinally importnat compounds, it was considered of interest to
synthesized some new indazoles which have been described as under.
SECTION - I   : Synthesis and biological evaluation of ethyl-4-[4-(methyl

















Type (IX) R = Aryl
Type (X) R = Aryl
7Cyclohexenones of Type (X) have been prepared by the cyclocondensation
of chalcones of Type (I) with ethylacetoacetate in the presence of  basic catalyst
K2 CO3
 SECTION-II :  Synthesis and biological evaluation of 6-[4-(Methylsulfo
     nyl)pheny]-4-aryl-2,3a,4-5-tetrahydro-3H-indazol-3-ones
Indazole derivatives of Type(XI) have been prepared by the reaction of
cyclohexenones of Type(X) with  hydrazine hydrate.
PART - VII    :   STUDIES ON ISOXAZOLES
Isoxazole derivatives represent one of the modest classes of compound
possessing wide range of therapeutic activities, such as antidepressants, skeleton
muscle relaxant, antidiabetic, anti-inflammatory, analgesic etc. With a view to
mapping better medicinal value and to evaluate its pharmacological profile, we have
synthesized some new isoxazole derivatives, which have been described as under.
SECTION - I  : Synthesis and biological evaluation of 3-[4-Methyl















Type (XII) R = Aryl
Type (XI) R = Aryl
8Isoxazole derivatives of Type(XII) have been prepared by the reaction  of
chalcones of Type(I) with hydroxylamine hydrochloride  in presence of sodium
acetate in acetic acid.
PART - VIII    :   STUDIES ON THIAZOLIDINONES
Compounds bearing thiazolidinone nucleus show wide range of biological
activity such as antimicrobial, CNS depressant, antiinflammatory, antitubercular,
sedative, anticonvulsant, analgesic and antihypertensive. With a view to suppliment
these valid observations, the synthesis of some new thiazolidinones have been
undertaken which have been descried as under.
SECTION - I  : Synthes i s  and b io log ica l  eva luat ion  of  3 -Amino-5-
arylidine-2-methyl-2-[4-(methylsulfonyl)phenyl]-1,3-
thiazolidin-4-ones
The thiazolidinone derivatives of Type (XIII) have been undertaken by the
condensation of 3-amino-2-methyl-2-[4-(methylsulfonyl)phenyl]-1,3-thiazolidin-4-
one with different aldehydes in glacial acetic acid.
The constitution of the synthesised compounds have been characterised
using elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. Purity of all the compounds have been









Type (XIII) R = Aryl
9In vitro studies on multiple biological activities.
(I) Selected compounds have been evaluated for their in vitro  biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 mg/ml  using Rifampin as  standard  drug,
which have  been  tested  by  Tuberculosis Antimicrobial Acquisition
Co-ordinating Facility (TAACF), Alabama, U.S.A.
(II) All the compounds  have been also evaluated  for their antibacterial activity
 towards Gram positive and Gram negative bacterial strains and antifungal
activity  towards  Aspergillus  niger at  a  concentration  of  40mg/ml. The
biological activity of the synthesized compounds have been compared with
standard drugs.
    INTRODUCTION
STUDIES ON
  CHEMICAL ENTITES OF
THERAPEUTIC INTEREST
Studies on chemical entities...
Introduction...
10
Research programs for the discovery of new drugs and for improving the
evolution criteria are under way in many laboratories.  In addition knowledge of
specific constituents of the mycobacterium cell and their biochemical roles has
advanced considerably in the recent years and may permit a more rational approach
to the design of new drug action on specific targets.  Also, recent improvements in
the knowledge of the mechanism of action of available drugs and the biochemical
mechanism of resistance to them may be used as a basis for design new and better
weapons to fight the mycobacterial diseases.
The  cur ren t  env i ronment  fo r  d i scovery  and  deve lopment  o f  new
pharmaceuticals agents could hardly be ware challenging.  Public policies and
attitudes are requiring reduction in health care expenditures and increase efficiencies,
resulting in major health care reform in the United States.  At the sometime, major
diseases remain untreated and paradoxically, scientific progress continues with ever
increasing acceleration.
The last few decades have witnessed massive advances in biochemistry,
physiology, pharmacology and genetics. This has to a better understanding of working
the body at the molecular level. This in turn has resulted a much better understanding
of the structure and function of important drug targets e.g. enzymes and receptors
and that how drugs can be designed for these targets.
Advances in genetics engineering have been used to produce human proteins
and enzymes in fast growing microbial cells, allowing these molecules to be obtained
in far greater yields than if they were extracted from human tissue. This makes it
easier to study these micro molecules and to design drugs that will interact with
them. Mapping of human DNA through human genome project has immense
implications for medicinal chemistry.
INTRODUCTION
Studies on chemical entities...
Introduction...
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Advances in chemistry have made possible the synthesis of complexes
molecules. Enantiometry is an important process in medicinal chemistry since life is
inherently chiral and the drug targets within the body are chiral. As such, they can
distinguish between the enantiomers of a chiral drug, so the use of recemic drug is
inherently wasteful, since only one enantiomer is ideally designed to interact with
its target. Moreover, the existences of the “wrong” enantiomer could create problems
if it interacted with a different receptor, resulting inside effects.
            The focus of drug design has switched from structure oriented to target
oriented research, e.g. development of the antiulcer agent cimetidine . Histamine
was the lead compound for the project and various strategies were used to find an
analog that would prevent it fitting its receptor. Once an antagonist was developed,
a theory was proposed on how it might interact with the histamine receptor at a
molecular level. Further analogs were then synthesized to test theory and the theory
was continusally modified as required.
        In the nineteenth century, chemistry developed as a science, both in terms of
experimental procedures and scientific theory. Scientist isolated and purified single
compounds from natural extracts. Method of organic synthesis were developed that
helped chemists altering structures in a predictable way.
The chemists started separating out the various components of ancient
positions to discover whether a single compound was responsible for the medicinal
effect known as the active principle.
Drugs are chemicals of low molecular weight (~100-500) which interact with
macromolecular targets to produce a biological response. The biological response
may be therapeutically useful in the case of medicines or harmful in the case of
poisons. Most drugs used in medicine are potential poisons if taken in higher doses
than recommended.
Studies on chemical entities...
Introduction...
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Drugs are classified by their chemical structures. Drugs classified in this way
share a common structural feature and often share similar pharmacological activity.
For example, all penicillin’s contain a b-lactum ring and kill bacteria by the same
mechanism, as a result, this classification can sometimes be useful in medicinal
chemistry. However, it is not foolproof. Sulfonamides have a similar structure and
are mostly antibacterial. However some sulfonamides are useful in the treatment of
diabetes. Similarly all steroids have a tetracyclic structure, but the pharmacological
effect of different steroids can be quite different e.g. testosterone  is  a sex hormone.
Spironolactone is a diuretic .
Finally classifying drugs according to their molecular target is the most useful
classification as far as medicinal chemist is  concerned, since it allows a rational
comparison of the structure involved.
Any drug must ideally have a broad spectrum of activity, with a rapid
bactericidal action. Some bacteria produce enzymes that can inactivate or modify
antibiotics action. Some bacteria produce enzymes that can inactivate or modify
antibiotics and insusceptibility of a drug to such degradation or modification could
result in its playing an important part in therapy. Likewise, some bacteria possess
an outer membrane that acts as a permeability barrier to the entry of some, but not
all, antibiotics. Drugs that can readily penetrate this barrier might again be expected
to be of possible clinical importance.

























Studies on chemical entities...
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with his finding of prontosil red a compound responsible for the antibacterial activity.
In 1939 Florey and Chain investigate penicillin-G which was discovered ten years
earlier by Alexander Fleming.
The word drug is described from the french word drogue  which mean a dry
herb. According to WHO  a drug may be define as “Any substance or product which
is used or intended to be used for modifying on exploring physiological system or
pathological status for the benefit of the recipient.” There are two main division of
medicinal chemistry. The first chemotherapy, concern with the treatment of
infections, parasite or malignant disease by chemical agents, usually substance that
shows selective toxicity towards the pathogen.
During the period of 1940 to 1960 a large number of important drugs have
been introduced and this period is regarded as “Golden Period” of new drug
discovery. These are some of the specific examples representing new therapeutics.
NAME OF DRUGS YEAR USES






Adrenergic betablockers 1958 Coronary
Vasodilatory
Semi synthetic penicillins 1960 Antibacterial
Trimethoprim 1965 Antimicrobial
Disodium chromoglycoate 1967 Antiallergic
The other division relates to diseases of bodily disfunctioning of enzymes,
the transmission of impulses on the action of hormones on receptors. Heterocyclic
Studies on chemical entities...
Introduction...
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compounds are used for all these purpose, because they have a specific chemical
reactions. The introduction of heterocyclic groups in to drugs may effect their
physical properties, for examples the disscociation constants of sulpha drugs or
modify their patterns of absorption, metabolisam or toxicity.
During the period of 1930-1950 there was an urgent need for new drugs for
treat diseases which had a high mortality rate, there was only limited appreciation
of the hazard. Such drugs might present and toxicological studies before cinical
trials were fairly radimenting proving the proverb “Necessity is the mother
invention”, during the dacade of 30 and 40s.
Taking in view of the applicability of heterocyclic compounds, we have
undertaken the preparation of heterocycles bearing pyrazole nucleus. The placement
of a wide variety of substituents of these nuclei have been designed in order to
evaluate the synthesised products for their pharmacological profile against several
strains of bacteria and fungi.
AIM AND OBJECTIVES
In the pharmaceutical field, these have always been and will continue to be a
need for new and novel chemical inhibitors of biological function. Our efforts are
focused on the introduction of chemical diversity in the molecular from work in
order to synthesizing pharmacologically interesting compound of widely different
composition.
During the course of our research work, looking to the application of het-
erocyclic compounds, several entities have been designed, generated and character-
ized using spectral studies. The details are as under.
1. To synthesize therapeutically active compounds like pyrazolines,
cyanopyridines, cyanopyridones, cyanopyrans, pyrimidines, indazoles,
isoxazoles and thiazolidinones bearing methylsulfonyl moiety.
Studies on chemical entities...
Introduction...
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2. To generate several intermediates, like chalcones, cyclohexenone bearing
methanesulfonyl acetophenone moiety.
3. To characterize these products for structure elucidation using several spec-
troscopic techniques like IR, PMR and Mass spectral studies.
4. To assess the reaction and purity of the compounds were done by TLC.
5. To evaluate these products for better drug potential against different strains
of bacteria and fungi.
6. All the compounds have been sent to TAACF, southern Research institute,
and USA; for antitubercular testing.
Taking in to consideration the applicability of heterocyclic compounds, the
placement of variety of substituted in these nuclei has been designed in order to
evaluate the synthesized products for their better pharmaceutical profile.




The term “chalcone”  was first coined by Kotanecki, who did pioneering
work in the synthesis of natural coloring compounds. They are characterized by
their possession of a C6(A)-CO-CH=CH-C6(B), structure in which two aromatic
ring A and B, are linked by an aliphatic three carbon chain.
Chalcones are phenyl styryl ketones containing reactive keto-ethylinic group
(-CO-CH=CH-). They are also known as benzalacetophenones or benzylidene
acetophenones the alternatively names given to chalcone are b-phenyl acrylophenone,
a -oxo-a,b -diphenyl- b-propylene and a -phenyl- b-benzoyl ethylenes.
SYNTHETIC ASPECT
A variety of a methods are available for the synthesis of chalcones. The most
convenient method is the one that involves the Clasien-Schmidt condensation of
equimolar quantities of a aryl methyl ketones with aryl aldehyde in the presence of
alcoholic alkali.
1-3






























The chalcones have been found to be useful for the synthesis of many
heterocyclic compounds.
1. Chalcone contain a Keto-Ethylenic group and therefore reactive towards a
number of reagents yielding various heterocyclic compounds exhibiting

















2. Chalcones are intermediate compounds for the synthesis of some naturally
occuring heterocyclic compounds like flavones, flavanones, flavanoids,
dihydro flavanols, benzal coumarinones, anthocyanins etc.
3. The structure of some naturally occurring pigments like chrysin, galangin,
kaempferol and quercetrol were established by their synthesis from suitably
substituted chalcones.
24


















presence of Ba and Sr as it reacts with number of metal ions. Trihydroxy









































 and for spectrophotomatric study of the germanium.
33
6. The chalcones are natural biocides
34,35
 and are well-known key intermidiate
in the synthesis of heterocyclic compounds possessing biodynamic
behaviour.
36-38





, oganic brightening agent, photo
sensitive material, polymerisation catalyst, scintillators as well as fluorescent
whitening agent.
THERAPEUTIC IMPORTANCE
Chalcones derivatives have been found to possess wide range of therapeutic
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 probably owe their biological activity in the
presence of the a ,b-unsaturated carbonyl group. Nelson G. L. et al.
72
 synthesized
the analogs of prostaglandin (II).
The compound 4-[1-oxo-3-(3,4,5- t r imethoxyphenyl)-2-propenyl]-1-
piperazine acetic acid ethyl ester (III) has been marketed under the name of
‘Cinepazet’ used as vasodilator. The other 5-methoxy-2-methyl-1-(1-oxo-7-phenyl)-
1H-indole-3-acetic acid (IV) has been marketed under the name of ‘Cinmetacin’
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Some dihydrochalcones are well known for their sweetening property
73,74
 and appear
to be non-nutritive sweeteners. A dihydrochalcone ‘Uvaretin’ from Uvaria
acuminata has shown antitumor activity
75
 in lymphocytic leukemia test. V. K.
Ahluwalia et al.
76
 have noted that 5-cinnamoylchalcones (V) have shown good as
antibacterial activity.
Chalcones have served as starting material for several synthetic manipulations
and a versatile synthon in organic synthesis.
Moreover, Khatib S. et a1.
77
 synthesized some novel chalcones as potent
tyrosinase inhibitors(VI). Ko H. H. et al.
78
 have prepared chalcones and found active
against potent inhibition of platelet aggregation. Ziegler H. L. et al.
79
 reported some
novel chalcones as antiparasitic.
Go M. L. et al.
80
 have described the synthesis and biological activities of
chalcones as antiplasmodial. Xue C. X. et al.
81
 synthesized and reported chalcones
as antimalarial agents. Fu Y. et al.
82
 have synthesized Licochalcone-A
Furthermore, Alcaraz M. J. et al.
83
 have described the role of nuclear
factor-kappaB and heme oxygenase-1 in  the  mechanism of  act ion of  an
anti-inflammatory chalcone derivative in RAW 264.7 cells. Nerya O. et al.
84
 have
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STUDIES ON CHALCONE DERIVATIVES
PART - I :   STUDIES ON  PYRAZOLINES
PART - II :   STUDIES ON  CYANOPYRIDINES
PART - III :   STUDIES ON  CYANOPYRIDONES
PART - IV :   STUDIES ON CYANOPYRANS
PART - V :   STUDIES ON PYRIMIDINES
PART - VI :   STUDIES ON INDAZOLES
PART - VII :   STUDIES ON ISOXAZOLES
PART - VIII :   STUDIES ON THIAZOLIDINONES
Sabzevari O. et al.
85
 have constructed some new chalcone derivatives as
molecular cytotoxic mechanisms for anticancer activity (VII).
Recently, Ban H. S. et al.
86
 synthesized some novel chalcones as inhibition of
lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor
necrosis factor-alpha by 2'-hydroxychalcone derivatives in RAW 264.7 cells. Hollosy
F. et al.
87
 have prepared some new chalcones as plant-derived protein tyrosine kinase
inhibitors as anticancer agents.
Chalcone have been proved to be an important intermediate for the synthesis
of many heterocyclic compounds in organic chemistry. These facts pormpted us to
sythesize some novel  chalcone derivat ives bearing 1-[4-(methylsulfonyl)
phenyl]ethanone, in order to achiving better therapeutic agents, we have undaertaken










Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful framework for biological activities, Pyrazolines have
attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. In 1967 Jacobe,
reviewed the chemistry of pyrazolines, which have been studied extensively for their
biodyndmic behaviour
88
 and industrial applications.
89
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives  documented
in literature are as follows.
1. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines
90
.
2. Epoxidation of chalcones i.e. epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines
91
. Furthermore, B. Gyassi et al.
92
investigated the one pot synthesis of some pyrazolines in dry media under
microwave irradiation. S. Paul et al.
93
 and Dandia Anshu et al.
94
 have
also described the microwave assisted synthesis of 2-pyrazolines.
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The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate.
98
Nucleophilic attack by hydrazine at the b-carbon of the a,b -unsaturated
carbonyl system forms species, in which the -ve charge is mainly accomodated by
the electronegative oxygen attom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine. Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl carbon
followed by proton transfer from nitrogen to oxygen leads ultimately to carbonyl
amine. The later with a hydroxy group and amino group on the same carbon lose









































From the literature survey, it was revealed that 2-pyrazolines are better



































Moreover F. Manna and co-worker
119
 have described 1-acetyl-5-(2'-
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives
which acts as potent antiinflammatory, analgesic and antipyratic agents.Udupi R.
H. and Bhatt A. R.
120
 have reported the synthesis and biological activity of Mannich
bases of certain 1,2-pyrazolines. Nugent Richard
121
 investigated pyrazolines bis
phosphonate ester as novel antiinflammatory and antiarthritic agent. Fuche Rainer
et al.
122
 have prepared some new 1H-pyrazoline derivatives and reported them as
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pes t ic ides .  Fur thermore ,  Tsubai  e t  a l .
123
 have  syn thes ized  some  new
(phenylcarbamoyl) pyrazolines as an insecticides and at 40% concentration shows
100% mortality of spodopetra litura larve after seven drops.
Shulabh Sharma et al.
124
 have synthesized pyrazolines and tested their
antiinflammatory activity (II).Ashok Kumar et al.
125
 have synthesized pyrazolines
as anticonvulsant agents (III). Maurer Fritz et al.
126
 have synthesized pyrazoles and
screened for their pesticidal activity.
E. Palska et al.
127
 have prepared 3,5-diphenyl-2-pyrazolines (IV) and cited
their antidepressant activity. B. Shivrama et al.
128,129
 have synthesized pyrazolines as
antibacterial agents. Hiremath S. P. et al.
130
 have reported pyrazolines as analgesics,
antiinflammatory and antimicrobial agents. Malhotra V. et al.
131
 have synthesized
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Moreover, T. M. Stivensen et al.
132
 have also investigated N-substituted pyrazoline
type insecticides. Tanka Katsohori
133
 have patented pyrazoline derivatives as
herbicides and Johannes et al.
134
 as insecticides. Moritaz Z. and Hadol
135
  investigated
a semi emperial molecular orbital study on the reaction of aminopyrazolinyl azodye
with singlet molecular oxygen. Shivnanda M. K. and            co-workers
136
 have
prepared substituted pyrazolines and reported their antibacterial activity.
Almstead J. et al.
137
 have prepared pyrazolines as vascularization agents. Guniz
Kuchkguzel et al.
138
 have synthesized pyrazolines as a antimicrobial  and
anticonvalsant agents. Gulhan T. Z. and co-workers
139
 have prepared pyrazolines
as a hypotensive agent.
S. S. Sonarc et al.
140
 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. H.
Parekh
141
 et al. have also synthesized some new pyrazolines as an antimicrobial agent.
G. N. Mishirika et al.
142 have also prepared 2-pyrazolines of salicyclic acid  possessing
antimicrobial properties. Tunfawy, Atif and co-workers
143
 have patented 3-methyl-
4'-(substituted phenylazo)-pyrazol-5-ones as antibacterial agents.
Thus, significant biological  properties associated with pyrazoline derivatives
have aroused considerable interes to design the compounds with better drug
potentials and to study their pharmacological profile, which have been described as
under.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)1-
[ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 3 - A RY L - 2 -
PROPENE- 1-ONES
SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING O F 1 -
A C E T Y L - 3 - [ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 5 -
ARYL-4,5-DIHYDRO-1H-PYRAZOLES
SECTION-III : SYNTHESIS AND BIOLOGICAL SCREENING OF 3-[4-
( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 5 - A RY L - 4 , 5 -
DIHYDRO-1H-PYRAZOLES




SYNTHESIS AND BIOLOGICAL SCREENING OF ( 2 E ) - 1 - [ 4 -
(METHYLS U L F O N Y L ) P H E N Y L ] - 3 - A RYL-2-PROPENE-1-ONES
Chalcone derivatives occupy a unique place in the field of medicinal
chemistry due to wide range of biological activities exhibited by them, prompted
by these facts, the preparation of chalcones of type (I) have been carried out by
condensation of 1-[4-(methylsulfonyl)phenyl]ethanone with various aldehydes in
presence of catalytic amount of alkali.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),










































Type-(I) R = Aryl






Gram positive bacteria : Bacillus cocus
Bacillus subtillis
Gram negative bacteria : Proteus Vulgaris
Escherichia Coli
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Ampicillin, Benzyl penicillin,
Norfloxacin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Ampicillin, Benzyl penicillin, Norfloxacin, Greseofulvin and antifungal activity was
compared with viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin.
MICROBIOLOGICAL EVALUATION
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2916 2975-2950 144
-CH3 C-H str. (sym.) 2870 2880-2860  ,,
C-H def. (asym.) 1460 1470-1435  ,,
C-H def. (sym.) 1382 1390-1370  ,,
Aromatic C-H  str. 3087 3090-3030 145
C=C str. 1490 1540-1480  ,,
1089 1125-1090  ,,
Halide C-Cl str. 775 800-600 144
Sulfonyl SO2 str. 1182 1185-1165  ,,
Vinyl CH=CH str. 3028 3050-3000  ,,
Chalcone C=C str. 1564 1580-1550  ,,
C=O str. 1654 1672-1652  ,,








Studies on chemical entities...
Pyrazolines...
31
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.5 3 H singlet -SO2CH3 -
2 7.28-7.31 2 H doublet Ar-H b,b         Jba=8.1
3 7.35-7.40 2 H doublet Ar-H c,c         Jcd=8.7
4 7.47-7.52 1 H doublet CHe -
5 7.55-7.58 2 H doublet Ar-H a,a         Jab=8.4
7 7.71-7.76 1 H doublet CHf -




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz









































































































SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)-1-[4-(METHYL
SULFONYL)PHENYL]-3-ARY L-2-PROPENE-1-ONES
(A) Synthesis of  1-[4-(methylsulfonyl)phenyl]ethanone
           To the solution of 1-[4-(methylthio)phenyl]ethanone in glacial acetic acid
(10 ml), H2O2 (6 ml, 30%) was added and stirred for 5 hr. The stirred content was
kept at room temperature for 24 hr till a crystalline solid was seperated. The
seperated solid was filtered and recrystallized from ethanol Yield 80%, m.p118oC,
Anal. Calcd. for C9H10O3S : Require: C, 54.53, H, 5.08; Found: C, 54.51, H, 5.06
%.
(B) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -(p-chlorophenyl)- 2 -
propene-1-one
Dissolve 1-[4-(methylsulfonyl)phenyl]ethanone (1.98gm, 0.01mol) in (25 ml)
methanol, to this add p-chlorobenzaldehyde (1.40gm, 0.01mol) in (25 ml) methanol
and stirred at room temperature for 24 hr. in presence of catalytic amount of 40%
KOH. The resulting solution was poured on to crushed ice, thus the solid seprated
was filterated and crystallized from ethanol, Yield 58%, m. p. 120oC, Anal. Calcd.
for C16H13ClO3S Require: C, 59.91, H, 4.08 ; Found: C, 59.89, H, 4.05 %.
Similarly, other compound were prepared. The physical data are recorded in
Table No. 1




The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual
method was inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of Bacillus
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Subtilis, Bacillus Coccous, Escherichia coli, Proteus Vulgaris in separate conical
flasks at 40-50oC and mixed well by gentle shaking. About 25 ml content of the
flask was poured and evenly spreaded in a petridish (13 cm diameter) and allowed
to set for 2 hrs. The cups (10 mm diameter) were formed by the help of borer in
agar medium and filled with 0.04ml (40mg) solution of sample in DMF. The plates
were incubated at 37oC for 24 hrs. and the control was also maintained with 0.04ml
of DMF in a similar manner and the zone of inhibition of the bacterial growth were
measured in millimeter and recorded in Graphical Chart No. 1
(b) Antifungal activity
146
Aspergilus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabourauds agar slants
sterilized sabourauds agar medium was inoculated with 72 hrs. old 0.5ml suspension
of fungal spores in a separate flask. About 25ml of the inoculated medium was
evenly spreaded in a petridish (13cm diameter) and allowed to set for 2 hrs. The
cups (10mm diameter) were punched. The plates were incubated at 30oC for 48
hrs. After the completion of incubation period, the zone of inhibition of growth in
the form of diameter in mm was measure. Along the test solution in each petridish
one cup was filled up with solvent, which acts as control. The zone of inhibition of
test solution  are recorded in Graphical Chart No. 1
(C)Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordination Facility (TAACF), USA.
Primary screening of the compounds for the antitubercular activity have been
conducted at 6.25 mg/ml towards Mycobacterium tuberculosis H37Rv in BACTEC
12B using the BACTEC 460 radiometric system. The compounds demonstrating
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atleast>90% inhibition in the primary screening has been tested at lower
concentration towards Mycobacterium tuberculosis H37Rv to determine the actual
minimum inhibitory concentration (MIC) in the BACTEC-460.
The antitubercular data have been compared with standard drug Rifampin at
6.25 mg/ml concentration and it showed 98% inhibition. The primary screening
method is described as under.
Antitubercular activity was determined using the BACTEC 460 system as
modi f i ed  be low.  S tock  so lu t ions  as  t e s t  compounds  were  p repared  in
dimethylsulfoxidie (DMSO) at 1 mg/ml and sterilized by passage through 0.22 mm
PFTE filters (Millex-FG, Millipore, Bedford MA). Fifty microliters was added to
4ml radiometric 7H12 broth (BACTEC 12B; Becton Dickinson Diagnostic
Instrument System, Sparks, MD ) to achieve a final concentration of 6.25 mg/ml.
Controls received 50 ml DMSO. Rifampin(Sigma Chemical Co., St. Louis, MO)
was included as a positive drug control. Rifampin was solublized and diluted in
DMSO and added to BACTEC-12 broth to achieve a range of concentration for
determination of minimum inhibitory (MIC, lowest concentration inhibiting 99% of
the inoculum).
M. Tuberculosis H37Rv (ATCC 27294; American type culture collection,
Rockville, MD) was culture at 37oC on a rotary shaker in middlebrook 7H9 broth
(Difco Laboratories, Detroiet, MI) supplemented with 0.2 v/v glycerol and 0.05%
v/v Tween 80 until the culture turbidity achieved an optical density of 0.45-0.55 at
550nm. Bacteria were then pelleted by centrifugation, washed twice and resuspended
in one fifth the original volume in dulbecco’s phosephate buffered saline (PBS, Irvine
Scientific Santa, Nalgene, Rochester, NY) and aliquots were frozen at 80oC. Cultures
were showed and an appropriate dilution performed such that a BACTEC-12B vial
inoculated with a 0.1 ml would reach a growth index (GI) of 999 in 5 days.
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One tenth of diluted inoculum was used to inoculate 4 ml fresh BACTEC
12B broth containing the compounds. An additional control vial was included which
received a further 1;100 diluted inoculam (as well as 50 ml DMSO) use an calculating
the MIC of Rifampin, respectively by establishing procedures.
Cultures were incubated in 37oC and the GI determined daily until control
cultures achieved a GI og 999. Assays were usually completed in 5-8 days. Percent
inhibition was defined as-1-(GI of test sample/GI of control)x100. Minimum
inhibitory concentration of compound effecting a reduction in daily chang in GI,
which was less than that, observed with a 1:100 diluted control culture one day the
letter reached a GI of at least 30.
       The percentage of inhibition data of compounds are recorded in Table No. 2
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1a 182264 PD-61 C6H5 - Alamar H37R v >6.25 00
1b 182265 PD-62 4-Cl-C6H4 - Alamar H37R v >6.25 00
1c 182266 PD-63 2-Cl-C6H4 - Alamar H37R v >6.25 00
1d 182267 PD-64 3-Cl-C6H4 - Alamar H37R v >6.25 00
1e 182268 PD-65 4-OCH3-C6H4 - Alamar H37R v >6.25 55
1f 182269 PD-66 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
1g 182270 PD-67 4-F-C6H4 - Alamar H37R v >6.25 42
1h 182271 PD-68 4-Br-C6H4 - Alamar H37R v >6.25 00
1i 182272 PD-69 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
1j 182273 PD-70 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
1k 182274 PD-71 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-1
TAACF, Southern Research Insitute
Primary Assay Summary Report








ANTITUBERCULAR ACTIVITY OF (2E)- 1-[4-(METHYL S U L F O N Y L )
PHENYL]-3-ARY L-2-PROPENE-1-ONES





































































SYNTHESIS AND BIOLOGICAL SCREENING OF 1 - A C E T Y L - 3 - [ 4 -
(METHYLSULFONYL)PHENYL]-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
The broad spectrums of pharmacological properties have been demonstrated
by the pyrazoline nucleus. Inspired by these facts, new pyrazoline derivatives of
Type (II) have been investigated. The 1-[4-(methylsul fonyl )phenyl] -3-ary l -2-
propene-1-ones  of type-(I) on treatment with hydrazine hydrate in acetic acid
yielded 1- ace ty l -3- [4-(methylsulfonyl)phenyl]-5-aryl-4,5-dihydro-1H-pyrazoles
derivatives of type (II).
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2920 2975-2950 144
-CH3 C-H str. (sym.) 2850 2880-2860   ,,
C-H def. (asym.) 1490 1470-1435   ,,
C-H def. (sym.) 1357 1390-1370   ,,
Aromatic C-H  str. 3047 3090-3030 145
C=C str. 1544 1540-1480   ,,
1093 1125-1090   ,,
1010 1070-1000   ,,
Halide C-Cl str. 819 800-600 144
Sulfonyl SO2 str. 1188 1185-1165   ,,
Pyrazoline C=O str. 1658 1612-1593 145
C=N str. 1593 1612-1593   ,,


















































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.3 3 H singlet Ar-COCH3 -
2 2.4 3 H singlet Ar-SO2 CH3 -
3 3.03-3.11 1 H d,d Ar-Hf -
4 3.65-3.75 1 H d,d Ar-Hg -
5 5.49-5.55 1 H d,d Ar-He -
6 7.13-7.24 2 H doublet Ar-H b,b'         Jba=8.1
7 7.24-7.26 2 H doublet Ar-H c,c'         Jcd=8.6
8 7.27-7.28 2 H doublet Ar-H a,a'         Jab=8.7




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz


























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 1 - A C E T Y L - 3 - [ 4 -
(METHYLSULFONYL)PHENYL]-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-1-
ones
See Part-I, Section-I (B).
(B) Synthesis of 1-Acetyl-3-[4-(methylsulfonyl)phenyl]-5-(p-chlorophenyl)-
4,5-dihydro-1H-pyrazole
A mixture of 1- [4-(Methyls u l f o n y l ) p h e n y l ] - 3 - (p-chlorophenyl)- 2 -
propene-1-on e (3.20 gm, 0.01 mol) in glacial acetic acid (25 ml) and hydrazine
hydrate (0.5gm, 0.01 mol) was refluxed for 8 hrs. The product was  isolated and
crys ta l l ized  f rom e thanol .  Yie ld  56%,  m.p .  125o C,  Anal .  Ca lcd .  for
C18H17ClN2O3S; Requires: C, 57.35; H, 4.55; N, 7.43 %; Found: C, 57.32; H,
4.53; N, 7.45 %.
Similarly, other 1-acetyl-3-[4-(methylsulfonyl)phenyl]-5-aryl-4,5-dihydro-
1H-pyrazoles  were prepared. The physical data are recorded in Table No.2
(C) Biological screening of 1-Acetyl-3-[4-(methylsulfonyl)phenyl]-5-aryl-
4,5-dihydro-1H-pyrazoles.
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.2
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2a 182204 PD-1 C6H5 - Alamar H37R v >6.25 00
2b 182205 PD-2 4-Cl-C6H4 - Alamar H37R v >6.25 00
2c 182206 PD-3 2-Cl-C6H4 - Alamar H37R v >6.25 00
2d 182207 PD-4 3-Cl-C6H4 - Alamar H37R v >6.25 00
2e 182208 PD-5 4-OCH3-C6H4 - Alamar H37R v >6.25 55
2f 182209 PD-6 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
2g 182210 PD-7 4-F-C6H4 - Alamar H37R v >6.25 42
2h 182211 PD-8 4-Br-C6H4 - Alamar H37R v >6.25 00
2i 182212 PD-9 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
2j 182213 PD-10 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
2k 182214 PD-11 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-2
TAACF, Southern Research Insitute
Primary Assay Summary Report









ANTITUBERCULAR ACTIVITY OF 1 - A C E T Y L - 3 - [ 4 - (METHYL
SULFONYL)PHENYL]-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
















































































SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - [ 4 -
( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 5 - A R Y L - 4 , 5 - D I H Y D R O - 1 H -
PYRAZOLES
Therapeutic important of pyrazolines aroused considerable intrest to
synthes ize  pyrazol ines  of  type  ( I I I )  by  the  cyclocondensa t ion  of  1 - [ 4 -
(Methylsul fonyl)phenyl] -3-aryl -2-propene-1-ones of type-(I)  with hydrazine
hydrate in order to study their biodynamic behaviour.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.


























































IR SPECTRAL STUDIES OF 3-[4-(METHYLSULFONYL)PHENYL]-5-
(p-METHOXYPHENYL)- 4 , 5 - D I H Y D R O - 1 H - P Y R A Z O L E
Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2945 2975-2950 144
-CH3 C-H str. (sym.) 2879 2880-2860   ,,
C-H def. (asym.) 1436 1470-1435   ,,
C-H def. (sym.) 1398 1390-1370   ,,
Aromatic C-H  str. 3058 3090-3030 145
C=C str. 1510 1540-1480   ,,
1095 1125-1090   ,,
1066 1070-1000   ,,
Ether C-O-C str. 1245 1260-1200 144
Sulfonyl SO2 str. 1172 1185-1165   ,,
Pyrazoline N-H str. 3340 3400-3200 145







Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.5 3 H singlet Ar-SO2 CH3 -
2 3.9 3 H singlet Ar-OCH3 -
3 2.95-3.04 1 H d,d Ar-Hc -
4 3.36-3.45 1 H d,d Ar-Hg -
5 4.84-4.90 1 H d,d Ar-He -
6 6.85-6.89 2 H doublet Ar-H b,b'         Jba=8.1
7 7.22-7.25 2 H doublet Ar-H c,c'         Jcd=8.6
8 7.26-7.30 2 H doublet Ar-H a,a'         Jab=8.7




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 3-[4-(METHYLSULFONYL)PHENYL]-5-
















































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - [ 4 -
( M E T H Y LS U L F O N Y L ) P H E N Y L ] - 5 - A R Y L - 4 , 5 - D I H Y D R O - 1 H -
PYRAZOLES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-
1-ones
See Part-I, Section-I (B).
(B) Synthesis of 3-[4-(Methylsul fonyl)phenyl] -5-(p-methoxyphenyl)-4,5-
dihydro-1H-pyrazole
A mixture of 1-[4-(Methyls u l f o n y l ) p h e n y l ] - 3 -(p-methoxyphenyl) - 2 -
propene-1-one (3.16 gm, 0.01 mol) in methanol (25 ml) and hydrazine hydrate
(0.5gm, 0.01 mol) was refluxed for 8 hrs. The product was  isolated and crystallized
from ethanol. Yield 63%, m.p. 168oC, Anal. Calcd. for C17H18N2O3S; Requires:
C, 61.80; H, 5.49; N, 8.48 %; Found: C, 61.78; H, 5.48; N, 8.46 %.
Similarly, other 3-[4-(methylsulfonyl)phenyl]-5-aryl-4 ,5-dihydro-1H-
pyrazoles were prepared. The physical data are recorded in Table No.3
(C) Biological screening of 3-[4-(Methylsulfonyl)phenyl] -5-aryl-4 ,5-
dihydro-1H-pyrazoles .
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.3
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llluslea & Febiger , (Philadelphia), USA , 180; Biol. Abstr.,  1977,  64 , 25183




Pyridine is the parent of the series of compounds that is important in
pharmaceutical, agriculture and industrial chemistry. Among a wide range of pyridines
3-cyanopyridines acquired a special attention due to their wide range of therapeutic
activities. Most derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However
the simple pyridine compounds are prepared by the cyclization of aliphatic raw
materials.
The pyridine nucleous is found in a large number of commonly used drugs
which have diverse pharmacological activities. Interest in the synthesis of
multicyclic pyridine containing compounds have increased in recent years because
of their biological and pharmacological activities. In our continuation work in the
chemistry of pyridine nucleous, we have undrtaken the synthesis of methylsulfonyl
derivatives such as 2-methoxy-6-[4-(methylsulfonyl)phenyl]-4-phenylnicotinonitrile
via chlacones.
SYNTHETIC ASPECT :




1. Samour  and co-worker
7  
 have prepared substi tuted cyanopyridines by






































































The reaction proceeds through conjugate addition of active methylene















The extensive use of cyanopyridine derivatives have been established in medicine
due to its antihypertensive, anticholestemic, antidiabetic, antifungal and antibacterial



















The synthesis of cyanopyridines are of current interest owing to their
enormous occurence in biologically active derivaties. Hence, considerable attention
has been focused on the study of efficient and pharamaceutical important
cyanopyridines bearing benzimidazole nucleus.
El-Nabawia et al.
17
 have prepared 2-amino-3-cyano pyridine derivatives (I)
and studied their antimicrobial activity. S. Guru et al.
18
 have synthesized various
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 The insecticidal activity of cyanopyridines have been screened by Y. Sasaki
19
et al. Umed Ten et al.
20
 have prepared cyanopyridines as agrochemical fungicides.





 prepared cyanopyridine derivatives which inhibit cerebral
edema and delayed neuron death. hence, they are useful as cerebral edema inhibitors
or cerebrovascular disorder remedies.
S. S. Verma et al.
23
 and M. D. Ankhiwala
24
 have synthesized 2-amino-3-cyano-
2,6-disubstituted pyrimidines and studied their biological activities. Several workers
have prepared cyanopyridine derivatives and reported their cholinesterase
inhibi tors ,
25
 ant ihis taminic  and ant ia l lergic ,
26








 activities. Some new 3-cyanopyridine derivatives
synthesized by Hammama A. and coworkers
31
showed anticancer and anti HIV-I
activity. Abdallah N. et al.
32
 have synthesized and reported analgesic and
antiinflammatory activity.
Moreover Miertus et al.
33
 synthesized 2-formyl pyridine thiosemicarbazone
as a carcinostatic agent. Adriano Afonso et al.
34
 have found cyanopyridines are
Fernesyl  protein t ranferase inhibi tors .  Hussain et  a l .
35
 have  synthes ized
cyanopyridines as antimicrobial agent. Wu Wenxue et al.
36
 have synthesized
cyanopyridines as histamine H3 antagonists. Saudi Manal N. S. et al.
37
 have found
that cyanopyridines have fascialicidal property. Harada Hironori et al.
38
 have prepared
cyanopyridines and screened for their large conductance calcium activated
potassium channel opener activity.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a
valuable therapy for diabetes. Edwin B. Villhauer and co-worker
39
 have reported
the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor
class and a solution-phase synthesis that is practical up to the multikilogram scale.
One compound, NVP-DPP728 (III), is profiled as a potent, selective and shortacting
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DPP-IV inhibitor that has excellent oral bioavailability and potent antihyperglycemic
activity.
Marco J. L. et al.
40
 have synthesized of acetylcholinesterase inhibitors.
Moustafa M. A. et al.
41
 have prepared antibacterial agents. Rosentreter Ulrich et
al.
42
 have synthesized a new cyanopyridine as receptor agonists in the treatment of
cancer disease , inflammation, neurodegenerative disease(IV). Gary T. Wang and
co-worker
43
 have synthesized of o-trifluoromethylbiphenyl substituted 2-amino-
nicotinonitriles as inhibitors of farnesyltransferase(V).
Thus, diverse biological activities have been encountered in compounds
containing cyanopyridine ring system. Therefore it was considered wothwhile to
synthesise cyanopyridine derivatives which have been described as under.































SYNTHESIS AND BIOLOGICAL SCREENING OF 2-METHOXY-6-[4-
(METHYLSULFONYL)PHENYL]-4-ARYLNICOTINONITRILES
Cyanopyridines play a vital role owing to their range of biological and
physiological activites. In the light of these biological activities and variety of
industrial applications, some new 2-methoxy-6-[4-(methylsulfonyl)phenyl]-4-
a ry ln i co t inon i t r i l e s  derivatives of type (IV) have been prepared, by the
cyclocondensation of 1-[4-(methylsulfonyl)phenyl]-3-aryl-2-propene-1-ones of
type (I) with malononitrile in presence of sodium methoxide.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.


























































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2923 2975-2950 44
-CH3 C-H str. (sym.) 2852 2880-2860  ,,
C-H def. (asym.) 1448 1470-1435  ,,
C-H def. (sym.) 1380 1390-1370 ,,
Aromatic C-H  str. 3028 3090-3030 45
C=C str. 1494 1540-1480  ,,
1091 1125-1090  ,,
1010 1070-1000  ,,
Halide C-Cl str. 819 800-600 44
Sulfonyl SO2 str. 1184 1185-1165  ,,
Ether C-O-C str. 1209 1260-1200 ,,
Pyridine C=C str. 1606 1650-1520 45
C=N str. 1577 1580-1550 ,,
Nitrile C=N str. 2221 2240-2120 ,,








Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.4 3 H singlet Ar-SO2 CH3 -
2 3.9 3 H singlet Ar-OCH3 -
3 7.25-7.31 2 H doublet Ar-H b,b          Jba=7.8
4 7.40-7.46 2 H doublet Ar-H c,c         Jcd=8.4
5 7.43 1 H singlet Ar-He -
6 7.57-7.60 2 H doublet Ar-H a,a         Jab=8.1




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz





































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 2-METHOXY- 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-4-ARYLNICOTINONITRILES
(A) Synthesis of 1-[4-(Methyl su l fony l )pheny l ] -3 -aryl-2 -propene -
1 -ones
See Part-I, Section-I (B).
(B) Synthesis  of  2-Methoxy-6-[4-(methylsulfonyl)phenyl]-4-(p-chloro-
phenyl)nicotinonitrile
To a solution of 1-[4-(methylsu l fony l )pheny l ] -3 -(p-chlorophenyl)- 2 -
p r o p e n e - 1 - o n e  (3.20 gm, 0.01 mol), malononitrile (0.60gm, 0.01 mol)  in
methanol (10ml) and sodium methoxide, which prepared from sodium (46mg) and
absolute methanol (20ml) was added. The content was heated under reflux with
stirring for 12 hr. The reaction mixture was diluted with water and extracted with
chloroform. The excess solvent was distilled off and residue was crystallized from
ethanol. Yield 48%, m.p. 165oC, Anal. Calcd. for C20H15ClN2O3 S; Requires:
C,60.22; H, 3.79; N, 7.02; Found: C, 60.20 ; H, 3.78; N, 7.01 %.
S i m i l a r l y ,  o t h e r  2 - m e t h o x y - 6 - [ 4 - ( m e t h y l s u l f o n y l ) p h e n y l ] - 4 -
arylnicotinonitriles were prepared. The physical data are recorded in Table No.4
(C) Biological screening of 2-Methoxy-6-[4-(methylsul fonyl )phenyl] -4-
arylnicot inonitr i les
Antimicrobial testing were carried out as described in Part-I Section-1 (C).
The zones of inhabition of test solution are recorded in Graphical Chart No 4.
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Pyridone, which belongs to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Pyridones, with a carbonyl group at position 2 (I) have been subject of extensive
study in recent past. Numerous reports have appeared in the literature, which
highlight their chemistry and use.
Pyridones are derivatives of pyrimidines with carbonyl group at 2-position (I).
Some 2-pyridones are physiologically as well as pharmacologically important which
are as under, eg. amrinone (II), ciclopirox (III) and methylprylon (IV).
SYNTHETIC ASPECT :
1. G. Simchen and G. Entemman
1
 have synthesised 2-pyridone in which the ring
nitrogen comes from a nitrile group in acyclic precursor.
2.    K. Folkers and S. A. Harris
2
 have synthesised 3-cyano-2-pyridone by
      the condensation of cyano acetamide with 1,3-diketone or 3-ketoester.
3. M. A. Sluyter and co-workers
3












































 have prepared heteroaryl pyridones as GABA a,b  ligands (V).
Pednekar
15
 synthesized fused 2-pyridone derivatives (VI), (VII) and (VIII) as useful
heterocyclic moieties as they possess broad spectrum of biological activities such
as antiviral, CNS depressant, bactericidal and ulcer inhibitor.
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Morishita Koji et al. 
22
 have synthesized m-(2-oxo-l,2-dihydropyridyl) urea
derivatives (IX) possessing cholesterol acyltransterase (ACAT) inhibitory activity
and are useful for the treatment of hyperlipidemia and arteriosclerosis.





,  SH2 domain inhibitor
25





 have prepared pyridinyl methyl substituted pyridines and pyridones as
angiotensin II antagonists. H. Posnes
28
 reported 2-pyridones as physiologically active
compounds. Devdas Balekudru et al.
29
 prepared substituted  pyridinones (X) as
modulators of P38 NAP kinase.
Furthermore, Stenzel Wolfgang et al.
30
 reported some pyridone derivatives
(XI) as cardiotonic, hypnotics, antiasthematics and antithrombotic. Fischer Reiner
et al.
31





















 have prepared pyridinylmethyl substituted pyridines
and pyridones as angitensin II antagonist. Mukhtar Hussain Khan and co-workers
33,34
have prepared 2-pyridone derivatives (XIII) and (XIV) which possess insecticidal
and pesticidal activity.
These observations prompted us to combine this nucleous into well known
pharmaceutical properties of cyanopyridone nucleous so as to enhance the over all
activities of resulting moiety, which have described as under.














































SYNTHESIS AND BIOLOGICAL SCREENING OF 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-2-OXO-4-ARYL-1,2DIHYDROPYRIDINE-
3-CARBONITRILES
In view of powerful biological activities shown by cyanopyridones, like
antimicrobial and antitubercular, it was worthwhile to synthesized some cyano
pyridone derivatives possessing better biological activity. Synthesis of some new 6-
[4-(methylsulfonyl)phenyl]-2-oxo-4-aryl-1,2dihydropyridine-3-carbonitriles of
type(V)  car r ied  out  by  cyclocondensat ion  of  chalcones  of  type(I )  wi th
ethylcyanoacetate in presence of ammonium acetate as under.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),


























































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2918 2975-2950 35
-CH3 C-H str. (sym.) 2856 2880-2860 ,,
C-H def. (asym.) 1439 1470-1435 ,,
C-H def. (sym.) 1363 1390-1370 ,,
Aromatic C-H  str. 3043 3090-3030 36
C=C str. 1490 1540-1480 ,,
1091 1125-1090 ,,
1031 1070-1000 ,,
Halide C-Cl str. 813 800-600 35
Sulfonyl SO2 str. 1186 1185-1165 ,,
Amide C=O str. 1739 1740-1690 ,,
Amine N-H str. 3249 3180-3140 ,,
Nitrtile C=N str. 2218 2240-2120 ,,
IR SPECTRAL STUDIES OF 6-[4-(METHYLSULFONYL)PHENYL]-2-









Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.4 3 H singlet Ar-SO2CH3         -
2 6.6 1 H singlet Ar-He                   -
3 6.69 1 H singlet Ar-NH                 -
4 7.32-7.39 2 H doublet Ar-H b,b          Jbc=8.1
5 7.41-7.44 2 H doublet Ar-H c,c          Jcd=8.4
6 7.54-7.57 2 H doublet Ar-H a,a          Jab=8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 6-[4-(METHYLSULFONYL)PHENYL]-2-



























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-2-OXO-4-ARYL-1,2DIHYDROPYRIDINE-
3-CARBONITRILES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-
1-ones
See Part-I, Section-I (B).
(B) Synthesis of 6-[4-(Methylsulfonyl)phenyl]-2-oxo-4-(p-chlorophenyl)-
1,2dihydropyridine-3-carbonitrile
To a solution of 1-[4-(methylsu l fony l )pheny l ] -3 -(p-chlorophenyl)- 2 -
propene-1-one (3.20 gm, 0.01 mol), ethylcyanoacetate (1.13 gm, 0.01 mol) and
ammonium acetate (5.92gm, 0.08mol) in dioxan(25ml) was refluxed for 8 hr. The
resulting mixture was poured on to crushed ice. The product was isolated and
crys ta l l ized  f rom e thanol .  Yie ld  52%,  m.p .  185o C,  Anal .  Ca lcd .  for
C19H13ClN2O3S; Requires: C, 69.30; H, 3.40; N, 7.28; Found: C, 69.28; H, 3.49
N, 7.25 %.
S i m i l a r l y ,  o t h e r  6 - [ 4 - ( m e t h y l s u l f o n y l ) p h e n y l ] - 2 - o x o - 4 - a r y l -
1,2dihydropyridine-3-carbonitriles  were prepared. The physical data are recorded
in Table No.5
(C) Biological screening of 6-[4-(Methylsulfonyl)phenyl]-2-oxo-4-aryl-
1,2dihydropyridine-3-carbonitriles
Antimicrobial testing were carried out as described in Part-I Section-I(C).
The zones of inhibition of test solution are recorded in Graphical Chart No 5.
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5a 182252 PD-49 C6H5 - Alamar H37R v >6.25 00
5b 182253 PD-50 4-Cl-C6H4 - Alamar H37R v >6.25 00
5c 182254 PD-51 2-Cl-C6H4 - Alamar H37R v >6.25 00
5d 182255 PD-52 3-Cl-C6H4 - Alamar H37R v >6.25 00
5e 182256 PD-53 4-OCH3-C6H4 - Alamar H37R v >6.25 55
5f 182257 PD-54 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
5g 182258 PD-55 4-F-C6H4 - Alamar H37R v >6.25 42
5h 182259 PD-56 4-Br-C6H4 - Alamar H37R v >6.25 00
5i 182260 PD-57 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
5j 182261 PD-58 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
5k 182262 PD-59 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-5
TAACF, Southern Research Insitute
Primary Assay Summary Report










ANTITUBERCULAR ACTIVITY OF 6-[4-(METHYLSULFONYL)PHENYL]-
2-OXO-4-ARYL-1,2DIHYDROPYRIDINE-3-CARBONITRILES





















































































1. G. Simchen and G. Entenmann;
Angew. Chem. Int. Edn Engl, 12 , 119 (1973).
2. K Folkers, S. A. Harris;
J. Am. Chem. Soc., 61 , 1245 (1939).
3. M. A. Sluyter, U. K Pandit, W. N. Speckamp and H. O. Huisman;
Tetranedron Lett., 87   (1966).
4. Hu Zhiyong, Wang Huicai;
Chem. Abstr., 119 , 72465d (1993).
5. U. Toru, T. Susumu, E. Masayuki and S. M. Saharu;
Eur. Pat. Appl. EP. 4 88 , 220 (Cl. C07D 413/04) (1992); Chem. Abstr., 118 , 80944d (1993).
6. R. W. Hartann, N. Reichert and S. Gozhring;
Eur. J. Med. Chem., 29(11), 807-17 (1994); Chem. Abstr., 122 , 239500n (1995).
7. K. Jonhannes, F. Rainer, J. R. Jansen and S. Nichael;
Ger. Offen. DE 4, 309 , 552 (Cl. C07/D 213/85); Chem. Abstr., 122,   9877m (1995).
8. D. D. Erol, N. Yulung and A. Turk;
Eur. J. Med. Chem., 29(11), 893-7 (1994); Chem. Abstr., 122, 13650a (1995).
9. P. Fey, H. K Rudolf, H. Walter and K Thomas;
Eur. Pat. Appl. Ep. 62, 3611, (Cl. C07D 401/14); Chem. Abstr., 122, 55897r (1995).
10. H. Rudolf, H. Walter, D. Juergen and F. Peter;
Eur. Pat. Appl. Ep. 5 57 , 843 (Cl. C07D 401/12); Chem. Abstr., 120 , 8478d (1994).
11. H. Michael, Haesslein Jean-Iuc and H. Bertrand ;
PCT Int. Appl. WO   93   16, 149 (Cl. C07D211/86); Chem. Abstr., 120 , 106778w (1994).
12. R. Bernd, P. A. Schirwan, R. Dieter, R. Guenther;
PCT. Int. Appl. WO 96 30, 342 (Cl. C07D 213/89); Chem. Abstr., 126 , 7993e (1997).
13. F. Al-Omar, A. Abdul Zahar, A. El-Khair, A. Adel;
Chem. Abstr ., 136 , 309834q (2002).
14. I. J. Collins, L. P. David and M. C. Richard;
PCT Int. Appl. WO 98 55 , 480 (1998); Chem. Abstr., 130 , 38376t (1999).
15. Pedneker;
PCT Int. Appl. WO 98 30 , 342 (1998); Chem. Abstr., 130 , 487191 (1999).
16. J. E. Reiner, Lim-Wilby,   R. S. Marge, T. K Brunck and Ha-Vong;
Chem. Lett., 9(6), 895-900 (1999); Chem, Abstr., 131 , 286379a (1999).
17. Y Mikio, I. Voshiniro, S. Atsushi, Y. Mitsuhiro and H. Rgo;
Jpn. KokaiTokkyo Koho JP II 140 , 054 (Cl. C07D 213/64); Chem. Abstr., 131 , 44738a




18. R. Betageri, L. Beaulieu, B. Pierrel ;
PCT Int. Appl. WO 99 31, 066 (Cl. C07D213/75); Chem. Abstr., 131 , 59136a (1999).
19. S. Asmaa, S. Salem;
Pharmazie 54(3), 178-183 (1993); Chem. Abstr., 130 , 281907k (1999).
20. H. Timothy, M. Christopher, R. laewis, R. Thomas;
PCT Int. Appl. WO 98  10 , 384 (Cl. C07D 471/14); Chem. Abstr., 130 , 13918h (1999).
21. B. Shivakumar and L. G. Nargund;
Indian J. Heterocyclic Chem., 8(1), 27-36 (1998); Chem. Abstr., 130 , 66428e (1999).
22 M. K Morishita, A. Nagisa and J. Masashi;
PCT Int. Appl. WO 99 43, 659 (Cl. C07D 213/72); Chem. Abstr., 131 ,
170353h (1999).
23 Reiner John E., Lim Wilby, Margeu Rita S., Bruncj Terence K. and Ha-Vong Theresa;
Chem. Lett ., 9(6) , 895-900 (1999); Chem. Abstr ., 131 , 286379a (1999).
24. Yamagudi Mikio, Ito Voshiniro, Shibaytama Atsushi, Yomaji, Mitsuhiro and Hanai Rgo;
Jpn. Kokai Tokkyo Koho JP 11 140,054 (Cl. CO7D 213/64) ; Chem. Abstr ., 131 , 44738a
(1999).
25. Betageri Rajashekhar, Beaulieu Llinas Brunet, Pierrel;
PCT Int. Appl . WO 99  31,066 (Cl. CO7D 213/75); Chem Abstr. , 131 , 59136a (1999).
26. Harison Timothy, Moyes Christopher, Richard Laewis, Richard Thomas;
PCT Int. Appl . WO 98  10,384 (Cl. CO7D 471/14); Chem. Abstr ., 130 , 13918h (1999).
27. Peter Fey, Dressel Juergem, Kanko Rudolf, Huebsch Walter and Kraemer Thomas;
Eur. Pat. Appl.  EP  62  3611 (Cl. CO7D 401/14); Chem. Abstr ., 122 , 55897x (1995).
28. H. Gary Posnes;
Org. Synth ., 177 (1994). chem. Abstr. , 123 , 167349g (1996).
29. Devdas, Balekudru, Walker, John, Selnes, Shaun R., Boehm, Terril., Durley, Richard C.,
Devraj, Rajesh, Hickory, Brian S., Rucker, Paul V., Jerome, Kevin D.;
PCT Int. Appl.  WO 03 68 , 230 (Cl. A61K31/4412), 21 Aug 2003, US Appl.
PU 436,915, 30 Dec 2002; 1052 pp.
30. Stenzel, Wolfgang; Hofferber, Eva.;
Eur. Pat. Appl.  E.P. 167,121 (Cl. CO7D213/85), 08 Jan 1986, DE Appl. 3,424,685, 05
Jul 1984; 26 pp.
31. Fischer, einer, Ullmann, Astrid, Trautwein, Axel, Drewes, Mark-Wilhelm, Erdelen,
Christoph, Dahmen, Peter, Feucht, Dieter, Pontzen, Rolf, Loesel, Peter.;
Studies on chemical entities...
Pyridones...
94
Der. Offen. DE 10 , 100,175 (Cl. C07D417/04), 11 Jul 2002.
32. F. Peter, D. Juergem, H. Rudolf, H. Walter and K Thomas;
Eur. Pat. Appl. EP. 62  3611 (Cl. C07D 401/14); Chem. Abstr., 122 , 55897r (1995).
33. Mukhtar Hussain Khan, Raizul Haque;
Indian J. Chem., 37(B) , 1069 (1998).
34. Mukhtar Hussain Khan, Raizul Haque, Taruna Agrawal;
Indian J. Chem., 38(B) , 452-456 (1999).
35. V. M. Parikh;
“ Absorption spectroscopy of organic molecules”, Addition-Wesley Pub. Co. London 243,
258 (1978). A. Hand book of spectroscopic data by B. D. Mishtry; 1st ed. ABD Press
Jaipur 11-36 (2000).
36. A. R. Kartizky and R. Alans Jones;
J. Chem. Soc., 2942 (1960). Introduction of Infra fed and Raman spectroscopy by Norman
B. Colthup, Lowrence H. Daly and Stephan E. Wiberluy. Academic Press (1975).




The chemistry of pyran with different functional group exhibit wide range of
applications in the field of pharmaceuticals, dyes, insecticides and sweet smelling
substances. Pyran ring system is also present in large number of natural coloured
compounds in Vitamin E, hemorrhagic compound in cloves, in fish poisions, in certain
alkaloids and in other substances.
Pyran is a doubly unsaturated six membered ring system with a single oxygen
as hetero atom. The two double bonds may be conjugated as a,b or 1,2-pyran or
isolated as in a,d or 1,4-pyran.
A degree of stabilisation of the pyran nucleus is achieved by substituting
phenyl group in the 2 or 4 and preferably also in the 6 position.
SYNTHETIC ASPECT
































The reaction of malononitrile with a,b -unsaturated system leads to the
formation of cyano 4H-pyran via Michael addition as shown in figure.
THERAPEUTIC IMPORTANCE
Literature survey revealed that various pyrans have resulted in many potential
drugs and are known to possess a broad biological spectrum such as,
1. CNS active agent
12
2. Cytotoxic 13
3. Inhibitors of cell proliferation14
















































 have synthesized cyanopyran derivatives and
showed their antiviral activity. Corbou Romuld et al.
31
 have reported cyanopyran
derivatives (III) which have significant pharmacological activity.












Synthesis and biological activity of pyran ring system have been reported by O’Brien
et al.
38
Sharanin Y. U. A. et al.
39






















 have newly synthesized pyran derivatives show
antiashamatic activity. Boyer Frederick et al.
41
 have prepared some new 2-amino-3-
cyano-4H-pyran and reported for anti HIV agent and antiviral activity.
Synthesis and anticancer activity of pyran (VI) containing flourine have been
reported by Mohamed S. Abd et al.
42
 4H-pyran of type (VII) were prepared to
enhance the anticancer and anti HIV activity.
Moreover, Fathy F. Abdel-Latif et al.
43
 have reported the synthesis of 2-amino-
3-cyanopyran derivatives and studied their biological activity. Piao Minz, Zhu et.
al.
44
 have prepared biologically active 2-amino pyran derivatives.
Recently, Hanafusa T, et al
45
 have reported some new cyanopyran as functional
promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor
specific methylation. Williamson H. S. et al
46
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protein from enteropathogenic Escherichia coli acts as an antagonist. Yeo H. and Li
Y. et al.
47
 have described the synthesis and antiviral activity of helioxanthin analogues.
David-Cordonnier M. H. et al.
48
 have synthesized as antitumor agents.
Morever, Asche C. et al.
49
 have reported some novel cyanopyran as antitumour
activity and structure-activity relationships of 5H-benzo[b]carbazoles. Moon C.H.
et al.
50
 have found some novel benzopyran analog, attenuates hypoxia-induced cell
death via mitochondrial KATP channel and protein kinase C-epsilon in heart-derived
H9c2 cells. Howe A.Y. et al.
51  have described some novel nonnucleoside inhibitor





Thus, diverse biological activities have been encountered in compounds
containing cynopyran ring system. Therefore it was considered wothwhile to
synthesized cyanopyran derivatives containing methylsulfonyl derivatives which have
been descried as under.
SECTION-I :SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-
 6 - [ 4 -(METHYLSULFONYL)PHENYL]-4-ARYL-4H-PYRAN-3-
 CARBONITRILES




SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - A M I N O - 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-4-ARYL-4H-PYRAN-3-CARBONITRILES
Cyanopyran derivatives have been found to be associated with various
pharmacological activities. These findings encouraged us to synthesized, some new
2-amino-6-[4-(methylsulfonyl)phenyl]-4-aryl-4H-pyran-3-carbonitrile derivatives of
type (VI) by the cyclocondensation of 1-[4-(methylsulfonyl)phenyl]-3-aryl-2-
propene-1-ones  of type-(I) with malononitrile in pyridine.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),




























































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed  Reported
Alkane C-H str. (asym.) 2922 2975-2950 53
-CH3 C-H str. (sym.) 2837 2880-2860 ,,
C-H def. (asym.) 1461 1470-1435 ,,
C-H def. (sym.) 1346 1390-1370 ,,
Aromatic C-H  str. 3004 3090-3030 54
C=C str. 1514 1540-1480 ,,
1095 1125-1090 ,,
1028 1070-1000 ,,
Halide C-Cl str. 821 800-600 53
Sulfonyl SO2 str. 1180 1185-1165 ,,
Pyran C=C str. 1566 1650-1520 54
Nitrile C=N str. 2204 2240-2120 53
Amine N-H str. 3352 3380-3350 ,,








Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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    (dppm)
 Relative No.
  of protons
Multiplicity Inference
1 2.5 3 H singlet Ar-SO2 CH3    -
2 5.39 1 H singlet Ar-He    -
3 7.33-7.36 2 H doublet Ar-Hb,b’ Jba=8.4
4 7.46-7.49 2 H doublet Ar-H c,c’ Jcd=8.1
5 7.49 2 H singlet Ar-NH2               -
6 7.55-7.56 2 H doublet Ar-H a,a’          Jab=8.7
7 7.56-7.62 2 H doublet Ar-H d,d’         Jdc=8.3















  J Value
    In Hz



































































































(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-
1-ones
See Part-I, Section-I (B).
B) Synthesis of 2-Amino-6-[4-(methylsulfonyl)phenyl]-4-(p-chlorophenyl)-
4H-pyran-3-carbonitrile
To a solution of 1-[4-(Methylsu l fony l )pheny l ] -3 -(p-chlorophenyl)- 2 -
propene-1-one. (3.20 gm, 0.01 mol) and malononitrile (0.66gm, 0.01 mol) dissolved
in pyridine (20 ml). The content was heated under reflux for 10 hr. on oilbath. The
reaction mixture was cooled and poured on to crushed ice. The residue was
neutralized with 20% HCl, where upon a solid separated out, which was filtered
and crys ta l l ized  f rom ethanol .  Yie ld  58%,  m.p .143o C Anal .  Ca lcd . for
C19H15ClN2O3S; Requires: C,58.99; H, 3.91; N, 7.24 %; Found: C, 58.98; H,
3.89; N, 7.23 %.
Similarly, other 2-amino-6-[4-(methylsulfonyl)phenyl]-4-aryl-4H-pyran-3-
carbonitriles  were prepared. The physical data are recorded in Table No.6
(C) Biological screening of 2-Amino-6-[4-(methylsulfonyl)phenyl]-4-aryl-
4H-pyran-3-carbonitriles
Antimicrobial testing were carried out as described in Part-I, Section-I(C).
The zones of inhibition or test solution are recorded in Graphical Chart No.6
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6a 182240 PD-37 C6H5 - Alamar H37R v >6.25 00
6b 182241 PD-38 4-Cl-C6H4 - Alamar H37R v >6.25 00
6c 182242 PD-39 2-Cl-C6H4 - Alamar H37R v >6.25 00
6d 182243 PD-40 3-Cl-C6H4 - Alamar H37R v >6.25 00
6e 182244 PD-41 4-OCH3-C6H4 - Alamar H37R v >6.25 55
6f 182245 PD-42 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
6g 182246 PD-43 4-F-C6H4 - Alamar H37R v >6.25 42
6h 182247 PD-44 4-Br-C6H4 - Alamar H37R v >6.25 00
6i 182248 PD-45 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
6j 182249 PD-46 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
6k 182250 PD-47 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-6
TAACF, Southern Research Insitute
Primary Assay Summary Report










ANTITUBERCULAR ACTIVITY OF 2-AMINO-6-[4-(METHYLSULFONYL)
PHENYL]-4-ARYL-4H-PYRAN-3-CARBONITRILES
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Pyrimidine is the most important member of all the diazines as this ring  system
occurs widely in living organisms. Pyrimidine and its derivatives have gained
prominence bacause of their potential pharmaceutical values. Many pyrimidine
derivatives play vital role in many physiological action. They are among those
molecules that make life possible as being some of the building blocks of DNA and
RNA.
Pyrimidine is considered to be a resonance hybrid of the charged and
uncharged cannonical structures, its resonance energy has been found to be less
than benzene or pyridine. The naturally occuring pyrimidine derivatives was first
isolated by Gabrial and Colman in 1870, and its structure was confirmed in 1953 as
5-b-D-gluco-pyranoside of divicine.
SYNTHETIC ASPECT
A very important general method for preparing pyrimidines is the condensation
between a three carbon compounds of the type YCH2Z, where Y and Z = COR,
CO2R, CN, and compounds having the amidine structure R(C=NH)NH2, where R
= R (an amidine), OH (urea), SH or SR (thiourea or its s-derivative), NH2
(guanidine); the condensation is carried out in the presence of sodium hydroxide or
sodium ethoxide. This general reaction may be illustrate by the condensation of
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Pyrimidines can also be prepared by cycloaddition reaction of 1,3,5-
triazines,which act as electron deficient dienes.
There are many other methods of pyrimidine ring synthesis which are of more
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent
with formamide provides a route of several pyrimidine which are unsubstituted at
the 2-position.
Some other examples of pyrimidine synthesis are as under.
REACTION MECHANISM










































It is revealed from the literature survey that pyrimidine derivatives have been





















S. S. Sangapure and S. M. Mulagi
11
 have tested the antimicrobial activity of
benzofuro[3,2-d]pyrimidine derivatives (II). El Sayed
12
 and A. M. Badaway have






































R2 = SH, NH 2














































their anticancer and antineoplastic activity. H. Y. Moustafa
13
 have reported some
pyrimidine derivatives and studied their biological activities.
The pyrimidines uracil (IVa), thyamine (IVb) and cytosine (V) occur very
widely in nature since they are components of nucleic acids, in the form of N-
substituted sugar derivatives. Several analogues have been used as compounds that
interfere with the synthesis and functioning of nucleic acids: examples are fluorouracil
(IVc) and the anti-AIDS drug Zidovudine (AZT) (VI). Some diaminopyrimidines ,
including pyrimethamine (VII) and trimethoprim (VIII) are antimalarial agents;
trimethoprim is also an effective antibacterial agent when used in combination with
a sulphonamide. Minoxidil (IX) is a vasodilator which has been used in the treatment






































Patil L. R. et al.
14
 have synthesized some new pyrimidines bearing paracetamol
and imidazolyl moieties. B. J. Ghiya et al.
15
 synthesized some mercapto pyrimidine
derivatives (XI) and screened for their anticancer, antitubercular and anti HIV
activities.Kaplina N. V. and co-workers
16
 shows herpes inhibiting activity of some
mercapto pyrimidine derivatives.
Moreover, Chaudhari Bipinchandra et al.
17
 prepared N6-(2-aminopyrimidin-
4-yl)-quinoline-4,6-diamine (XII) as N-type calcium channel antagonists for the
treatment of pain. Devi E. Sree and co-workers
18
 have prepared pyrimidine
derivatives and tested for  antimicrobial activity. Kovalenko A. L.
19
 synthesized and
reported antifungal activity of pyrimidine derivatives. Shiv P. Singh and co-workers
20
synthesized 4-(4-pyrazolyl)-2-aminopyrimidines(H) and tested them for their
antimicrobial activity.
Some pyrazolo thienopyrimidine derivatives exhibit antiulcer activity
21
.
Skolova A. S. and co-workers
22
 have synthesized 5-amino-6-mercapto pyrimidine










 have prepared mercapto derivatives and screened for their antibacterial
and antifungal activity.
H. S. Joshi et al.25 have sythesized some new pyrimidines as antitubercular
and   atimicrobial activity(XIII).
Marie Gompel and co-worker
26
 have showed that meridianins inhibit various
protein kinases such as cyclin-dependent kinases, glycogen synthase kinase-3, cyclic
nucleotide-dependent kinases and casein kinase (XIV). Alistair H et al
27
 have
synthesized a novel series of aminopyrimidine IKK2 inhibitors which show excellent
in vitro  inhibition of this enzyme and good selectivity over the IKK1 isoform. The
relative potency and selectivity of these compounds has been rationalized using
QSAR and structure-based modelling (XV).
Aleem Gangjee et al.
28
 have designed and synthesized some novel analogues
of N -{4-[2-(2-Amino-4-ethylpyrrolo[2,3-d ]pyrimidin-5-yl)ethyl]benzoyl}-L-










Meridianin A OH H H H
Meridianin B OH H Br H
Meridianin C  H Br H H
Meridianin D  H H Br H
Meridianin E OH H H Br
Meridianin F  H Br Br H
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reductase (DHFR) and as antitumor agents (XVI). Antonello Mai et al.
29
 have
descr ibed  2 -a lky lamino-6- [1 - (2 ,6 -d i f luorophenyl )a lky l ] -3 ,4 -d ihydro-5-
alkylpyrimidin-4(3H)-ones (F
2
-NH-DABOs) 4, 5 belonging to the dihydro-alkoxy-
benzyl-oxopyrimidine (DABO) family and bearing different alkyl and arylamino side
chains at the C
2
-position of the pyrimidine ring were active against wild type (wt)
human immunodeficiency virus (HIV-1) and some relevant HIV-1 mutants(XVII).
Viney Lather and co-worker
30
  have been proposed to predict the anti-HIV
activity of dihydro (alkylthio) (naphthylmethyl) oxopyrimidines. These models are
capable of providing lead structures for development of potent but safe anti-HIV
agents(XVIII).
Gompel M et al.
31
 have prepared new family of protein kinase inhibitors
isolated from the ascidian aplidium meridianum. Mai A et al.
32
 have synthesized 5-
alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a
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belonging to the DABO family. Yamamoto I. et al.
33
 have reported some
oxopyrimidines searching for the novel antagonist or agonist of barbiturates to the




and 2,4-diamino-6(5H)-oxopyrimidines as antitumor activity.
Shimizu T., Kimura T. et al.
35
 have described N3-substituted uridine and
related pyrimidine nucleosides as antinociceptive effects in mice. Sanmartin C et
al.
36
 have prepared new symmetrical derivatives as cytotoxic agents and apoptosis
inducers. Agarwal A. et al.
37
 have synthesized 2,4,6-trisubstituted pyrimidine
derivatives as pregnancy interceptive agents.
Whittingham J. L. et al.
38
 have described pyrimidine ring as a platform for
antimalarial drug for the selectivity of a class of nucleoside inhibitors. Han G. Z. et
al.
39
 documented the  pyr imidine  der ivat ives  as  ant icancer  ac t ions  of  2-
methoxyestradiol and microtubule-disrupting agents in human breast cancer. Tack
D. K. et al.
40
 reported anthracycline vs nonanthracycline therapy for breast cancer.
Cano-Soldado P. et al.
41
 have described pyrimidine nucleous as interaction of
nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside
transporter-1 (SLC28A1). Gompel M. et al.
42
 have isolated  a new family of protein
kinase inhibitors from the ascidian aplidium meridianum. Junmei Wang et al.
43  have
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Looking to the diversified activities exhibited and in continuation of our work
on the synthesis of biologically active heterocycles, the synthesis and biological
screening of pyrimidine derivatives have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF 4 -
[ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 6 -
A RYLPYRIMIDIN-2(1H)-ONES
SECTION-II : SYNTHESIS AND BIOLOGICAL SCREENING OF 4-[4-
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-
2(1H)-THIONES
SECTION-III : SYNTHESIS AND BIOLOGICAL SCREENING OF 4-[4-
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-
2-AMINES




SYNTHESIS AND BIOLOGICAL SCREENING OF 4 - [ 4 -
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-2(1H)-ONES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. 4-[4-(methylsulfonyl)phenyl]-6-arylpyrimidin-
2(1H)-one  of type (VII) have been prepared by the condensation of 1-[4-
(methylsu l fony l )pheny l ] -3 -a ry l -2 -p ropene -1 -ones  of type-(I) with urea in
presence of catalytic amount of conc. HCl as shown under.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),



























































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2920 2975-2950 44
-CH3 C-H str. (sym.) 2856 2880-2860 ,,
C-H def. (asym.) 1460 1470-1435 ,,
C-H def. (sym.) 1394 1390-1370 ,,
Aromatic C-H  str. 3030 3090-3030 45
C=C str. 1514 1540-1480 ,,
1089 1125-1090 ,,
1029 1070-1000 ,,
Halide C-Cl str. 773 800-600 44
Sulfonyl SO2 str. 1182 1185-1165 ,,
Vinyl CH=CH str. 3025 3050-3000 45
oxopyri. C=O str. 1654 1672-1652 ,,









Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.5 3 H singlet Ar-SO2 CH3     -
2 7.35 1 H singlet Ar-Hf     -
3 7.46-7.51 2 H doublet Ar-H b,b’ Jba=8.1
4 7.66-7.77 2 H doublet Ar-H c,c’ Jcd=7.8
5 7.62 1 H singlet Ar-He      -
6 7.88-7.91 2 H doublet Ar-H a,a’ Jab=8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz










































































































SYNTHESIS AND BIOLOGICAL SCREENING OF
(A) Synthesis  of  1-[4-(Methylsulfonyl)phenyl]-3-aryl-2-propene-1-ones
See Part-I, Section-I (B).
(B) Synthesis of 4-[4-(Methylsul fonyl )phenyl ] -6-(p-chlorophenyl)
pyrimidin-2(1H)-one
To a solution of 1-[4-(methylsu l fony l )pheny l ] -3 -(p-chlorophenyl)- 2 -
propene-1-one. (3.20 gm, 0.01 mol)  and urea (0.60gm, 0.01 mol) in dioxane(15
ml) was refluxed in presence of alcoholic KOH for 10 hr. The excess solvent was
distilled off and the residue was neutralized with dilute HCl, the separated solid
was filtered out and crystallized from ethanol. Yield 48 %, m.p. 165oC Anal. Calcd.
for C17H13ClN2O3S Requires: C, 56.99; H, 3.63; N, 7.76 % Found: C, 56.96; H,
3.62, N, 7.74 %.
Similarly, other 4-[4-(methylsulfonyl)phenyl]-6-arylpyr imidin-2(1H)-
ones were prepared.The physical data are recorded in Table No. 7.
(C) Biological screening of 4-[4-(Methylsulfonyl)phenyl]-6-aryl
pyrimidin-2(1H)-ones
Antimicrobial testing were carried out as described in Part-I, Section-I(C).
The zones of inhibition of test solution are reported in Graphical Chart No. 7.
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7a 182216 PD-13 C6H5 - Alamar H37R v >6.25 00
7b 182217 PD-14 4-Cl-C6H4 - Alamar H37R v >6.25 00
7c 182218 PD-15 2-Cl-C6H4 - Alamar H37R v >6.25 00
7d 182219 PD-16 3-Cl-C6H4 - Alamar H37R v >6.25 00
7e 182220 PD-17 4-OCH3-C6H4 - Alamar H37R v >6.25 55
7f 182221 PD-18 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
7g 182222 PD-19 4-F-C6H4 - Alamar H37R v >6.25 42
7h 182223 PD-20 4-Br-C6H4 - Alamar H37R v >6.25 00
7i 182224 PD-21 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
7j 182225 PD-22 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
7k 182226 PD-23 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-7
TAACF, Southern Research Insitute
Primary Assay Summary Report









ANTITUBERCULAR ACTIVITY OF 4-[4-(METHYLSULFONYL)PHENYL]
- 6 - A RYLPYRIMIDIN-2(1H)-ONES




































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4 - [ 4 -
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-2(1H)-THIONES
Thiopyrimidines represent one of the most active classes of compounds
possessing a wide spectrum of biological activities, such as significant in vitro  activity
against unrelated DNA and RNA viruses including Polio Viruses, diuretic,
antitubercular spermidical etc. These valid observation led us to synthesize 4-[4-
(m ethylsulfonyl)phenyl]-6-arylpyrimidin-2(1H)-thiones of type (VIII)  by
cyclocondensation of 1-[4-(methylsulfonyl)phenyl]-3-aryl-2-propene-1-ones of
type-(I) and thiourea in presence of HCl as catalyst.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1 H nuclear  magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
The biological activities of synthesized compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),






























































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2918 2975-2950 44
-CH3 C-H str. (sym.) 2854 2880-2860  ,,
C-H def. (asym.) 1490 1470-1435  ,,
C-H def. (sym.) 1382 1390-1370  ,,
Aromatic C-H  str. 3045 3090-3030 45
C=C str. 1546 1540-1480  ,,
1087 1125-1090  ,,
1031 1070-1000  ,,
Sulfonyl SO2 str. 1182 1185-1165 44
Amine N-H str. 3342 3300-3150 45
C=C str. 1658  ,,








Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.5 3 H singlet Ar-SO2 CH3     -
2 7.26 1 H singlet Ar-NH     -
3 7.26-7.32 2 H doublet Ar-Hb,b’ Jba=8.4
4 7.52-7.61 5 H multiplet Ar-H(c-g)      -
5 7.94-7.96 2 H doublet Ar-Ha,a’ Jab=8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz


































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4 - [ 4 -
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-2(1H)-THIONES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2-propene-ones
See Part-I, Section-I (B).
(B) Synthesis of 4-[4-(Methylsulfonyl)phenyl]-6-(phenyl)pyrimidin-2(1H)-
thione
A mixture of 1-[4-(methylsulfonyl)phenyl]-3-phenyl-2-propene-one (2.86
gm, 0.01 mole) and thiourea (0.78gm, 0.01 mol)in dioxane(15 ml) was refluxed on
a oil-bath in presence of alcoholic KOH for 10 hr. The solvent was distilled off and
the residue was neutralized with dilute HCl, the separated solid was filtered out and
crystallized from ethanol. Yield 62 %, m.p. 182oC Anal. Calcd. for C17H14N2O2S2
Requires: C, 59.63; H, 4.12; N, 8.18 % Found: C, 59.61; H, 4.10, N, 8.19 %.
Similarly, other 4-[4-(m ethylsulfonyl)phenyl]-6-arylpyrimidin-2(1H)-
thiones  were prepared. The physical data are recorded in Table No. 8.
(C) Biological screening of 4-[4-(Methylsulfonyl)phenyl]-6-arylpyrimidin-
2(1H)-thiones
Antimicrobial testing were carried out as described in Part-I, Section-I(C).
The zones of inhibition of test solution are reported in Graphical Chart No. 8.
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8a 182228 PD-25 C6H5 - Alamar H37R v >6.25 00
8b 182229 PD-26 4-Cl-C6H4 - Alamar H37R v >6.25 00
8c 182230 PD-27 2-Cl-C6H4 - Alamar H37R v >6.25 00
8d 182231 PD-28 3-Cl-C6H4 - Alamar H37R v >6.25 00
8e 182232 PD-29 4-OCH3-C6H4 - Alamar H37R v >6.25 55
8f 182233 PD-30 3,4-(OCH3)2-C6H3 - Alamar H37R v >6.25 18
8g 182234 PD-31 4-F-C6H4 - Alamar H37R v >6.25 42
8h 182235 PD-32 4-Br-C6H4 - Alamar H37R v >6.25 00
8i 182236 PD-33 3-C6H5 O-C6H4 - Alamar H37R v >6.25 11
8j 182237 PD-34 4-N(CH3 )2-C6H4 - Alamar H37R v >6.25 00
8k 182238 PD-35 2-OH-C6H4 - Alamar H37R v >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
Strain
     %
Inhibi.
   MIC
 mg/ml
  TABLE  NO-8
TAACF, Southern Research Insitute
Primary Assay Summary Report









ANTITUBERCULAR ACTIVITY OF 4-[4-(METHYLSULFONYL)PHENYL]-
6-ARYLPYRIMIDIN-2(1H)-THIONES






































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4 - [ 4 -
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-2-AMINES
Compounds containing pyrimidine ring are widely distributed in nature. Many
amino pyrimidine derivatives are reported to possess different biological activities.
In view of these findings, it was considered worthwhile to synthesize some new 4-
[4 - (methylsulfonyl)phenyl]-6-arylpyrimidin-2-amines of type-(IX) to study their
biological activities. Amino pyrimidine derivatives of type-(IX) have been prepared
by the reaction of the chalcones of type- (I) with guanidine hydrochloride in presence
of potassium tertiary-butoxide in tertiary-butanol shown as under.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.



















































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2920 2975-2950 44
-CH3 C-H str. (sym.) 2852 2880-2860 ,,
C-H def. (asym.) 1436 1470-1435 ,,
C-H def. (sym.) 1355 1390-1370 ,,
Aromatic C-H  str. 3085 3090-3030 45
C=C str. 1645 1620-1430 ,,
1089 1125-1090 ,,
1010 1070-1000 ,,
Halide C-Cl str. 804 800-600 44
Sulfonyl SO2 str. 1175 1185-1165 ,,
Pyrimidine C=N str. 1571 1580-1520 45
Primary Amine N-H str. 3336 3554-3350 ,,









Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.4 3 H singlet Ar-SO2 CH3     -
2 5.25 2 H singlet Ar-NH2     -
3 7.30-7.34 2 H doublet Ar-Hb,b’ Jba=8.7
4 7.37 1 H singlet Ar-He     -
5 7.42-7.46 2 H doublet Ar-Hc,c’ Jcd=9.6
6 7.96-7.97 2 H doublet Ar-Ha,a’ Jab=8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz









































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4 - [ 4 -
(METHYLSULFONYL)PHENYL]-6-ARYLPYRIMIDIN-2-AMINES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2-propene-ones
See Part-I, Section-I (B).
(B) Synthesis of 4-[4-(Methylsulfonyl)phenyl]-6-(p-chlorophenyl)pyrimidin-
2-amine
A mixture of 1-[4-(methylsulfonyl)phenyl]-3-(p-chlorophenyl) -2-propene-
1-one. (3.20 gm, 0.01 mol)  and guanidine hydrochloride (1.10gm, 0.01 mol) in
dioxane (20 ml) was refluxed on oil-bath in presence of alcoholic KOH for 8 hr. The
excess solvent was distilled off and the residue was neutralized with 20 % HCl, the
separated solid was filtered out and crystallized from ethanol. Yield 51 %, m.p.
166oC Anal. Calcd. for C17H14ClN3O2S Requires: C, 56.74; H, 3.92; N, 11.68 %
Found: C, 56.72; H, 3.91, N, 11.67 %.
Similarly, other 4-[4-(methylsulfonyl)phenyl]-6-arylpyrimidin-2-amines were
prepared. The physical data are recorded in Table No. 9.
(C) Biological screening of 4-[4-(Methylsulfonyl)phenyl]-6-arylpyrimidin-
2-amines
Antimicrobial testing were carried out as described in Part-I, Section-I(C).
The zones of inhibition of test solution are reported in Graphical Chart No. 9.
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INTRODUCTION
Cyclohexenone is the parent of a series of compounds that is important in
agricultural and medicinal chemistry. Cyclohexenones are derivatives of cyclohexane
with carbonyl group at 1-position and double bond at 2-position (I). Cyclohexenones
can be conveniently synthesized by the treatment of a,b - unsaturated carbonyl
compounds with ethylacetoacetate in basic media.
In recent years cyclohexenone derivatives have gained lots of interest because
of its prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the synthesis of cyclohexenone derivatives have been
described in literature.
1-7
1. N. Nanjundaswami et al.
8
 have prepared 6,7-dimethoxy-1-aryl-4-oxo-2-
naphthoate derivatives (II) by the reaction of dimethoxyphenyl aryl ketone
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MECHANISM
The addition reaction between ethylacetoacetate and a,b -unsaturated ketone
give cyclohexenone via Michael addition. This reaction has been carried out in basic
media by using sodium ethoxide or anhydrous K2CO3 in acetone. During the reaction
nucleophillic addition of carbanion take place to the C=C of the acceptor. The a,b -
unsaturated compound is known as acceptor and ethylacetoacetate is known as donor.
THERAPEUTIC EVALUATION
Cyclohexenone and its derivatives are widely used in pharmaceutical industry.
Considerable interest has been shown in the chemistry of cyclohexenones due to
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Hermann S.  e t  a l .
19
 have  repor ted  cyc lohexenones  as  he rb ic ides .
Anticonvulsant activity of some cyclohexenone derivatives (III) have been reported
by Natalie D. et al.
20
 Bastiaan and co-workers
21
 have synthesized novel cyclohexenone
derivatives (IV) which are useful in the treatment of parkinson’s disease.
Cyclohexenones (V) as anticancer and antiinflammatory agents have been
investigated.
22
Cyclohexenone derivatives which possess plant growth regulatory activity
have  been  repor ted .
23,24
 Nagao et al.
25
 have  repor ted  cyc lohexenones  as
antiarrhythmic.Collins and co-workers
26
 have documented estrogenic activity of
cyclohexenones. Tvanov et al.
27
 have reported antimicrobial activity of some
cyclohexenone derivatives. V. K. Ahluwalia and co-workers
28
 have assessed
cyclohexenone derivatives for anti HIV-I, gastric secretion inhibitors and pesticidal
activity. Cyclohexenone derivatives have been reported to be active as allergy
inhibitors, platelet aggregation inhibitors and fibrinogen antagonist.
29
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. Takehiro and co-workers
31
 have reported cyclohexenones
possessing neutropeptide b-receptor antagonist activity. Kimura and co-workers
32
have prepared cyclohexenones as inhibitory activity of penienone and remarkable
inhibitory activity against the growth of lettuce seedlings. Broughton H. et al.
33
have demonstrated cyclohexenones as GABA a,b-5 receptor ligands for enhancing
cognition properties.
Rheinheimer J .  et  al .
34
 have synthesized 5-(dioxabicyclohept-6-yl)
cyclohexenone oxime ethers as herbicides and plant growth regulators. Harimaya
and co-workers
35
 have synthesized new cyclohexenone derivatives possessing
progesteron receptor binding inhibitory activity. The herbicidal activity of
cyclohexenone derivatives (VI) has been investigated.
36
Zhang C. et al.
37
 have prepared tricyclic heterocycles, containing furan and
cyclohexenone nucleus for treating hyper-proliferative disorders.
With a view to getting better therapeutic agent, it was contemplated to
synthesized cyclohexenones bearing furan nucleus to enhance the overall activity of
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INTRODUCTION
Heterocyclic compounds bearing 1,2-diazole ring system i.e. pyrazole ring
system, attached to benzene ring system are known as benzopyrazole or indazole
(I). Indazole was first described by Buchner in 1869.
Although the chemistry of indazoles has been extensively studied, they have
not been found in natural products and are at the present time of little commercial
use.Indazole can be considered as either azaindazoles or azaisoindazoles.The
compounds of medicinal interest in this group so far have been non-steridol
antiinflammatory agents or analgesic.
SYNTHETIC ASPECT




1. Cyclocondensation of activated acetylenes with hydrazine afforded indazole
derivatives.
44
2. B. V. Badami et al.
45  have synthesized indazoles from chalcone derivatives
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3. A facile synthesis of substituted indazoles from 2-acyl mesylates and
hydrazines has been described by Caron S. et al.
46
THERAPEUTIC EVALUATION
It is revealed from the literature survey that indazole derivatives are better
























 have synthesized indazole derivatives and
evaluated them as antiinflammatory and analgesic activity. Malmstroem J.et al.
59
have prepared indazoles (II) as inhibitors of Jun N-terminal kinases (JNK).
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system diseases have been synthesized.
60
Butera J. A. et al.
61 have prepared some indazole derivatives which showed
antihypertensive, muscle relaxant and potassium activator activity. Several workers







 etc. Some indazole derivatives investigated as a
novel antiasthametic agents.
65
 Ooe T. et al.
66
 synthesized indazoles which have been
found to possess varied biological activities such as hematinics, immunostimulants
and antitumor agents. The remarkable cytotoxic activity of indazoles have been
reported.
67
Some indazoles (IV) have been synthesized by Duzinska-Usarewicz et al.
68
and found to possess antiinflammatory activity. Effland R. et al.
69
 synthesized 3-
(pyridyl amino)-indazoles (V) and reported as antidepressant and anxiolytics.
Newshaw R. and co-workers
70
 have prepared 4-amino ethoxy indazoles and
reported them as dopamine D2 agonists. Kania R. et al.
71
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derivatives as protein kinase inhibitors. Indazole derivatives are reported as inhibitors
of cell proliferation.
72
 The remarkable antipsychotic activity
73
 of indazoles (VI) have
been reported.
Lavielle G. et al.
74
 prepared [(pyrolidinyl) methyl]-indazoles and suggested
them for the treatment of migrains. Marfat Anthony
75
 has patented indazole
derivatives as phosphodiesterase and tumor necrosis factor production inhibitors.





 of indazoles have been reported. Badran M. et al.
78
 synthesized some novel
indazole derivatives by fusing with triazines and triazoles for exploring their
antiinflammatory activity.
Moreover, Hwang I. T. et al.
79
 have synthesized some new 2-phenyl-4,5,6,7-
tetrahydro-2H-indazole derivatives as paddy field herbicides. Tanitame A. et al.
80
have reported the designed, synthesized and studied structure-activity relationship
of novel indazole analogues as DNA gyrase inhibitors with Gram-positive
antibacterial activity(VII). Nasr M. N. et al.
81
 have prepared some novel 3,3a,4,5,6,7-
hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory
agents. Pinna G. A. et al.
82
 have described the synthesis of Chromophore-modified
bis-benzo[g]indole carboxamides.
Recently, Abouzid K. A. et al.
83
 have Synthesized and demonstrate anti-
inflammatory activity of novel indazolones. Wang Q. et al.
84,85
 have described the








Z = (un)-substituted piperazine
pyridino etc(VI)
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pyridinemethylaminoacrylates. Kakimoto T. et al.
86
 have prepared some novel
3,3a,5,9b-tetrahydro-2H-furo[3,2-c][2] benzopyran derivatives of chiral glycol
benzyl ether herbicides. Ikeguchi M. et al.
87
 have documented the synthesis and
herbicidal activity of new oxazinone herbicides with a long-lasting herbicidal activity
against Echinochloa oryzicola.
Among variety of pharmacological properties have been encountered with
indazole systems, keeping the above in mind some novel indazole derivatives have
been synthesized which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING O F
ETHYL-4-[ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 2 -
O X O - 6 - A R Y L C Y C L O H E X - 3 - E N E - 1 -
CARBOXYLATES
SECTION - II : SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[4-
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-4-[4-
(METHYLS U L F O N Y L ) P H E N Y L ] - 2 - O X O - 6 - A RY L C Y C L O H E X - 3 -
E N E - 1 -CARBOXYLATES
Cyclohexenones are endowed with variety of pharmacodynamic activities such
as anticonvulsant,antidiabatic etc. Looking to the interesting properties of
cyclohexenones aroused considerable interest  to synthesis  of  e thyl-4-[4-
(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 - a r y l c y c l o h e x - 3 - e n e - 1 -carboxylates  of the
type (X) by the cyclocondensation of 1-[4-(methylsu l fonyl )phenyl ] -3-ary l -2-
propene-1-ones  with ethylacetoacetate in the presence of anhydrous K2CO3 in
order to study their biodynamic behavior.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2920 2975-2950  88
-CH3 C-H str. (sym.) 2852 2880-2860   ,,
C-H def. (asym.) 1494 1470-1435   ,,
C-H def. (sym.) 1388 1390-1370   ,,
Aromatic C-H  str. 3080 3090-3030  89
C=C str. 1564 1540-1480   ,,
1095 1125-1090   ,,
1031 1070-1000   ,,
Ether C-O-C str. 1244 1080-1250  88
Sulfonyl SO2 str. 1159 1185-1165   ,,
Ester C=O-O str. 1741 1735-1717   ,,
Hexenone C=O str. 1675 1685-1665  89
(cyclo)
IR SPECTRAL STUDIES OF ETHYL-4-[4-(METHYLS U L F O N Y L )







Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
Studies on chemical entities...
        Indazoles...
158
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 1.04-1.25 3 H triplet Ar-CH2CH3     -
2 1.26-1.30 3 H singlet Ar-SO2 CH3     -
3 2.4 1 H singlet Ar-Hk     -
4 2.30 2 H quartet Ar-CH2CH3     -
5 3.99-4.03 1 H doublet Ar-Hh     -
6 3.74-3.96 1 H doublet Ar-Hj     -
7 2.72-2.76 1 H doublet Ar-Hi     -
8 2.77-3.07 1 H doublet Ar-Hl     -
9 7.21-7.23 2 H doublet Ar-Hb,b’ Jba=8.6
10 7.29-7.31 5 H multiplet Ar-H(c-g)     -




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL-4-[4-
(METHYLS U L F O N Y L ) P H E N Y L ] - 2 - O X O - 6 - A RY L C Y C L O H E X - 3 -
E N E - 1 -CARBOXYLATES
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-1-ones
See Part-I, Section-I (B).
(B) Preparation of ethyl-4-[4-(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 -phenyl-
c y c l o h e x - 3 - e n e - 1 -carboxylate
To a solution of 1-[4-(methylsul fonyl)phenyl] -3-(phenyl) -2-propene-1-
one (2.86 gm, 0.01 mol) in dry acetone, anhydrous K2CO3 (5.42gm, 0.04 mol) and
ethyl acetoacetate(2.60 gm, 0.02 mol) was added and the reaction mixture was stirred
at room temperature for overnight and was filtered. The solvent from the filtrate on
distill off gave a solid, which was crystallized from methanol to gave desired product
. Yield 45%, m.p. 164oC, Anal.Calcd. for C22H22O5S; Requires: C, 66.31; H, 5.56;
Found : C, 66.30; H, 5.54; %.
Similar ly,  other  e thy l -4 - [4- (methy ls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 -
a ry lcyc lohex-3-ene-1 - carboxylates were prepared. The physical data are recorded
in Table No.10
(C) Biological screening of ethyl-4-[4-(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 -
a r y l c y c l o h e x - 3 - e n e - 1 -carboxylates
Antimicrobial testing were carried out as described in Part-I, Section (C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.10
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SECTION - II
SYNTHESIS AND BIOLOGICAL SCREENING OF 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-4-ARYL-2,3a ,4,5-TETRAHYDRO-3H-
INDAZOL-3-ONES
The synthesis of indazole has attracted the attention of chemists because of
their potential pharmcodynamic properties. Looking to the interesting properties
of  indazoles ,  i t  appeared  of  in te res t  to  synthes ize  a  ser ies  of  6 - [ 4 -
(methylsulfonyl)pheny]-4-aryl-2,3a,4-5-tetrahydro-3H-indazol-3-ones of type (XI)
for obtaining biologically potent agents, which were prepared by reacting ethyl-4-
[4-(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 - a r y l c y c l o h e x - 3 - e n e - 1 -carboxylates  of
the type (X) with hydrazine hydrate in presence of glacial acetic acid.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.
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Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2981 2975-2950 88
-CH3 C-H str. (sym.) 2898 2880-2860  ,,
C-H def. (asym.) 1465 1470-1435  ,,
C-H def. (sym.) 1371 1390-1370  ,,
Aromatic C-H  str. 3028 3090-3030 89
C=C str. 1465 1540-1480  ,,
1118 1125-1090  ,,
1028 1070-1000  ,,
Ether C-O-C str. 1282 1150-1350 88
Sulfonyl SO2 str. 1176 1185-1165  ,,
Amide NH-C=O-str 1672 1680-1636  ,,
Indazole C=N str. 1573 1660-1480 89
Amine N-H str. 3228 3300-3140   ,,








Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 1.26 1 H singlet Ar-Hl     -
2 2.5 3 H singlet Ar-SO2 CH3     -
3 3.14-3.20 1 H d,d Ar-Hj     -
4 3.26-3.30 1 H d,d Ar-Hi     -
5 4.31-4.36 1 H d,d Ar-Hh     -
6 6.64 2 H singlet Ar-NH     -
7 7.27-7.34 5 H multiplet Ar-H(c-g)     -
8 7.36 1 H singlet Ar-Hk     -
9 7.34-7.43 2 H doublet Ar-Hb,b’ Jba=8.5




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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EXEPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6 - [ 4 -
(METHYLSULFONYL)PHENYL]-4-ARYL-2,3a ,4,5-TETRAHYDRO-3H-
INDAZOL-3-ONES
(A) Synthesis of 1-[4-(Methyl su l fony l )phenyl ] -3 -ary l -2 -propene-1-
ones
See Part-I, Section-I (B),
(B) Preparation of Ethyl-4-[4-(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 - a r y l
c y c l o h e x - 3 - e n e - 1 -carboxylates
See Part-VI, Section-I(B).
(C) Preparation of 6-[4-(Methylsulfonyl)phenyl]-4-phenyl-2,3a,4,5-tetra
hydro-3H-indazol-3-one
To a solution of  ethyl-4-[4-(methyls u l f o n y l ) p h e n y l ] - 2 - o x o - 6 -phenyl
c y c l o h e x - 3 - e n e - 1 -carboxylate (3.98gm, 0.01 mol) in ethanol (20 ml), hydrazine
hydrate (0.5gm 0.01 mol) and acetic acid (2 ml) was added. The content was refluxed
at 80oC for 4 hr on water bath. The residue obtained after cooling was filtered and
isolated. The product was crystallized from methanol. Yield 55 %, m. p. 134oC.
Anal. Calcd. for C20H18N2O3S Requires C, 65.95; H, 4.95; N, 7.64% Found C,
65.93; H, 4.92; N, 7.62%.
Similarly other, 6-[4-(methylsulfonyl)pheny]-4-aryl-2,3a,4-5-tetrahydro-3H-
indazol-3-ones  were prepared. The physical data are recorded in Table No. 11.
(C) Biological screening of 6-[4-(Methylsulfonyl)phenyl]-4-aryl-2,3a,4,5-
tetrahydro-3H-indazol-3-ones
Antimicrobial testing were carried out as described in Part-I, Section (C).
The zones of inhibition of test solutions are recorded in Graphical Chart No.11
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Isoxazole is a five membered heterocyclic compound having two hetero atom:
oxygen at position 1 and nitrogen at position 2. Claisen first reported an isoxazole
(I) for a product from the reaction of 1,3 diketone with hydroxylamine.
1
 It was
shown to possess typical properties of an aromatic system but under certain reaction
conditions. Particularly in reducing or basic media, it becomes very highly labile.
The next important contribution to the chemistry of isoxazoles was made by
Quelico
2
 in 1945, when he begain to study the formation of isoxazoles from nitrile
N-oxide and unsaturated compounds.
SYNTHETIC ASPECT
Isoxazoles can be prepared by various method, which are described as under.
1. Tayade V. B. et al.
3
 synthesized some new 3,5-diarylisoxazoles from the
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in
presence of alkali.
2. Dawood Kamal et al.
4
 prepared isoxazole derivatives from enamino
nitriles.
3. Crawley L. S. and Fan shawe W. J.
5
 prepared isoxazole from a,b -unsaturated
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4. J. F. Hansen and S. A. Strong
6
 synthesized isoxazole from a,b -unsaturated
ketones and N-bromo succinimide.
REACTION MECHANISM
THERAPEUTIC IMPORTANCE



















































































Aicher Thomas D. et al.
31
 reported isoxazoles (II) as hypoglycemic agents.
H. H. Parekh et al.
32
 have synthesis  3-(p-methoxyphenyl)-5-(2 '-chloro-7 '-
methylquinolin-3'-yl)-isoxazole (III) and studied thier biologcal activity.
Talley John and co-workers
33
 and Mishra et al.
34
 have synthesized isoxazoles
and reported their analgesic and antiinflammatory activities. Masatosh et al.
35
 have
documented synthesized isoxazole derivatives as analgesic agent. Some other drugs
viz. sulfisoxazoles  (IV) is a well known antibiotic and activicin  (V)
36
 is an antitumor
agent having isoxazole moiety.
Moreover, S. Rung and D. Dus
37
 have synthesized some new isoxazoles as
remedy for leukemia. M. Scobie and co-workers
38
 have prepared isoxazole
derivatives and studied their antitumor activity. G. Daidone et al.
39
 synthesized novel
3-(isoxazol-3-yl)-quinazolin-4-(3H)-one derivative and tested for their analgesic
































Some i soxazo les  a re  found  to  possess  he rb ic ida l
40-42




,  estrogen receptor modulators47




 have prepared isoxazoles having pesticidal activity. Some
excellent herbicidal results obtained by Reddy et al.
50
 C. B. Xue et al.
51
 have reported
on oral antiplatelet effect in dogs.
H. S. Joshi et al.
52
 have synthesized isoxazole derivatives (VI) and reported
their antitubercular and antimicrobial activity.
Salter M. W. et al .
53
 have prepared some novel isoxazole as cellular
neuroplasticity mechanisms mediating pain persistence. Matringe M. et al.
54
 have
reported some new p-hydroxyphenylpyruvate dioxygenase inhibitor-resistant plants.
Mehlisch D. R. et al.
55
 have synthesized isoxazole derivative as analgesic efficacy
of intramuscular parecoxib sodium in postoperative dental pain. Ray W. A. et al.
56
have reported isoxazole derivative as cardiovascular toxicity of valdecoxib.
Welsing P. M. et al.
57
 have documented the isoxazole as tumor necrosis factor-
blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Bingham S. J. et al.
58
 have synthesized as antiuclear. Barbachyn M. R. et al.
59
 have
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With an intension of preparing the compounds possessing better therapeutic
activity, we have under taken the preparation of isoxazoles bearing methylsulfonyl
derivatives which have been described as follows.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING O F 3 - [ 4 -
 METHYLS U L F O N Y L ) P H E N Y L ] - 5 -ARY LI S O X A Z O L E S




SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - [ 4 - M E T H Y L
S U L F O N Y L ) P H E N Y L ] - 5 - A RY L I S O X A Z O L E S
Isoxazoles have been reported to have various pharmacological activities
like antibacterial, antifungal, insecticidal etc. In order to achieving better drug
potency ,  we  have  prepared  i soxazole  der iva t ives  of  type  (XII )  by  the
cyclocondensation of 1-[4-(methylsulfonyl)phenyl]-3-aryl-2-propene-1-ones of
type(I) with hydroxylamine hydrochloride in presence of sodium acetate in glacial
aletic acid.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1 H nuclear  magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.




















































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2918 2975-2950 60
-CH3 C-H str. (sym.) 2854 2880-2860  ,,
C-H def. (asym.) 1411 1470-1435  ,,
C-H def. (sym.) 1344 1390-1370  ,,
Aromatic C-H  str. 3076 3090-3030 61
C=C str. 1512 1540-1480  ,,
1097 1125-1090  ,,
1037 1070-1000  ,,
Halide C-Cl str. 779 800-600 60
Sulfonyl SO2 str. 1159 1185-1165  ,,
Isoxazole C=C str. 1641 1680-1550 61
C=N str. 1600 1690-1460  ,,
N-O str. 835 850-810  ,,
IR SPECTRAL STUDIES OF 3-[4-METHYLS U L F O N Y L ) P H E N Y L ] -








Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.47 3 H singlet Ar-SO2 CH3     -
2 6.67-6.93 2 H doublet Ar-Hb,b’ Jba=8.7
3 7.05-7.07 2 H doublet Ar-Hc,c’ Jcd=7.8
4 7.25 1 H singlet Ar-He     -
5 7.45-7.46 2 H doublet Ar-Ha,a’ Jab=8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 3-[4-METHYLS U L F O N Y L ) P H E N Y L ] - 5 -



































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - [ 4 -
METHYLS U L F O N Y L )  P H E N Y L ] - 5 - A RY L I S O X A Z O L E S
(A) Synthesis of 1-[4-(Methylsu l fony l )pheny l ] -3 -aryl-2 -propene-1-ones
See Part-I, Section-I (B).
(B) Synthesis of 3-[4-Methyl s u l f o n y l ) p h e n y l ] - 5 - (p-chlorophenyl)-
i soxazo le
To a solution of 1-[4-(methyls u l f o n y l ) p h e n y l ] - 3 -(p-chlorophenyl)- 2 -
propene- 1-one  (3.20 gm, 0.01 mol) in ethanol (25 ml), anhydrous sodium acetate
(0.739gm, 0.01 mol) and hydroxylamine hydrochloride(0.59 gm, 0.01 mol) in acetic
acid were added. The reaction mixture was refluxed on oil bath for 7-8 hr. The
product  was isolated and crystallized from ethanol. Yield 56 %, m.p. 154oC Anal.
Calcd. For C16H12ClNO3S Requires ; C, 57.57; H, 3.62; N, 4.20; Found C, 57.56,
H, 3.61; N, 4.21%.
Similarly, other 3 - [ 4 -methyls u l f o n y l ) p h e n y l ] - 5 - a r y l i s o x a z o l e s  were
prepared. The physical data are recorded in Table No.12.
(C) Biological screening of 3-[4-Methyls u l f o n y l ) p h e n y l ] - 5 - a r y l
i s o x a z o l e s
Antimicrobial testing were carried out as described in Part-I Section-1 (C).
The zones of inhibition of test solution are reported in Graphical Chart No 12.
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Thiazolidinone, which belong to an important group of heterocyclic
compounds have been extensively explored for their applications in the field of
medicine. Thiazolidinones, with a carbonyl group at position 2 (I), 4 (II), and 5
(III), have been subjects of extensive study in the recent past. Numerous reports
have appeared in the literature which highlight their chemistry and use.
4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at 4
position (II) substituent in the 2,3 and 5 position may be varied, but the greatest
difference in structure and properties is exerted by the groups attached to carbon
atom at the 2-position and to nitrogen atom at the 3-position. The cyclic structure
was assigned after recognisation of mercaptoacetic acid as a primary products of
hydrolysis of 2-phenyl-3-phenylamino-4-thiazolidinones.
1
The chemistry of 4-thiazolidinones was reviewed in depth by F. Brown
2
 in




4-Thiazolidinones are synthesized either by cyclisation of acyclic compounds
or by interconversion among appropriately substituted thiazolidinone derivatives.
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R = Alky or aryl
R1 = Aryl or heterocyclic
R2 =  H or alkyl
R3 =  H or alkyl
R2, R3 = Arylidene
The substi tuted and unsubsti tuted a -mercapto alkanoic acids react
conveniently with Schiff’s bases of aromatic heterocyclic aldehyde and aliphatic or





The reaction proceeds by the attack of the mercapto acetic acid upon the
C=N group, with the HS-CH2-COOH adding to the carbon atom followed by the
capture of a proton by nitrogen and subsequent cyclisation.
In there reaction, the uncyclised intermediate is formed in several cases. The
uncyclised product has been isolated.
7
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for subsequent cyclisation of certain uncyclised products.
8
 In may instance 4-
thiazolidinones can conveniently be prepared by refluxing the mixture of
thioglycolic acid and Schiff’s bases in benzene




The nucleophilic attack of mercapto acetic acid anion on carbon of
azomethine, which has got possitive character while nitrogen has negative character
is evidenced, simultaneously removal of water as it forms in reaction, helps in
condensation and determination of the reaction time.
THERAPEUTIC IMPORTANCE
The thiazolidinones, substituted at 2 and 3 position showed a wide variety of
biologically activity. The frequent occurrence of the group HN-CO-NH or its
tautomer in compounds possess in vitro  tuberculostatic activity
12
.






































Moreover Albuquerque and co-workers
39
 have prepared 4-thiazolidinones
which show antidiabetic and antiinflammatory activity. Tagami et al.
40
 have
synthesized thiazolidinone derivatives as allergy inhibitor. Mohammad et al.
41
 have
prepared substituted thiazolidinones and reported their antibacterial, antifungal,
antithyroid and amoebicidal properties (V).
R. S. Lodhi and co-worker
42
 have been synthesized and studied antimicrobial,
antiinflammatory and analgesic property of 4-thiazolidinone and arylidene
derivatives (VI). Goel Bhawna et al.
43  have documented thiazolidinone derivatives
and compared their antiinflammation potency, ulcerogenic liability, cardiovascular
and CNS effect. Pawar and co-workers
44
 reported synthesis and in vitro antibacterial
activity of some 4-thiazolidinone derivatives. In other study, some thiazolidinone
















R1 = (un) Substituted aryl
Z = H2
Z = CH2R2
R1 , R2 = Substituted aryl
R1 = OH
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H. S. Joshi et al.
47
 have synthesized microwave assisted 4-thiazolidinones
and reported their biological activity.
Tamura et al.
48
 have reported antimicrobial activity of 4-thiazolidinone
derivatives. B. Lohary et al.
49
 have documented and reported hypolipidemic activity
of 4-thiazolidinone derivatives. Bhawana et al.
50
 have assessed some new 4-
thiazolidinones as antiinflammatory agents. Antifungal and antibacterial activity
51








 have prepared thiazolidinones and studied their herbicidal
activity. Archana and Srivastava
56
 have synthesized 4-thiazolidinones (VII) as potent
anticonvulsant agent. S. K. Srivastava et al.
57
 have formulated some new 4-
thiazolidinones (VIII) as antibacterial, antifungal, analgesic and diuretic agents.
Dayam R. et al.
58
 have reported some new thiazolidinone derivative as novel
class of HIV- integrase inhibitors. Sonawane N. D. et al.
59
 have synthesized some
new thiazolidinone derivatives as in vivo pharmacology and antidiarrheal efficacy
of CFTR inhibitor in rodents. Shih M. H. et al.
60
 have described the synthesis and
evaluation of antioxidant activity of sydnonyl substituted thiazolidinone and
thiazoline derivatives (IX).
Moreover, Salinas D. B. et al.
61
 documented the thiazolidinone derivatives
as CFTR inhibitor. Wang X. F. et al.
62

























Studies on chemical entities...
Thiazolidinones...
197
derivatives and described as new cystic fibrosis transmembrane conductance
regulator inhibitor on Cl- conductance in human sweat ducts. Ur F. et al.
63
 have
constructed some new 6-methylimidazo[2,1-b]thiazole-5-carbohydrazide derivatives
and studied their antimicrobial activities.
Furthermore, Reigada D.et al.
64
 have reported some novel thiazolidinone
derivatives as release of ATP from retinal pigment epithelial cells involves both
CFTR and vesicular transport.  Rao A. et al .
65
 have described some novel
thiazolidinone derivatives as 2-(2,6-dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-
4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Muanprasat C. et
al.
66 have prepared some new thiazolidinone derivatives as CFTR inhibitors.
Recently, Maclean D. et al.
67
 have reported thiazolidinone library as agonists
of the stimulating hormone receptor (X). Thiagarajah J. R. et al.
68,69
 have synthesized
a small molecule as CFTR inhibitor. Taddei A. et al.
70
 have been constructed some
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In view of the therapeutic activities of 4-thiazolidinones and methylsulfonyl
derivatives, it was contemplated to synthesis some new 4-thiazolidinones in search
of agents possessing higher biological activity with least side effect, which have
been described as under.
SECTION-I :  SYNTHESIS AND BIOLOGICAL SCREENING OF 3- AMINO-
  5 - A R YLIDINE-2-METHYL-2- [4 -METHYLSULFONYL)
  PHENYL]-1,3-THIAZOLIDIN-4-ONES




SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - A M I N O - 5 -
A RY LI D I N E - 2 - M E T H Y L - 2 - [ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 1 , 3 -
THIAZOLIDIN-4-ONES
4-Thiazolidinone and its derivatives represent one of the most active classes
of compounds possessing wide spectrm of pharmacological activity. Looking to
their versatile properties, it was planned to genarate a series of  3- am i n o - 5 -
arylidine-2-methyl-2-[4-(methylsulfonyl)phenyl]-1,3-thiazolidin-4-ones of type
(XIII) by heterocyclisation of 3-amino-2-methyl-2-[4-(methylsulfonyl)phenyl]-1,3-
thiazolidin-5-one with arylaldehyde acid.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1 H nuclear  magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40µg/ml.




































































Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2918 2975-2950 71
-CH3 C-H str. (sym.) 2839 2880-2860  ,,
C-H def. (asym.) 1431 1470-1435  ,,
C-H def. (sym.) 1398 1390-1370  ,,
Aromatic C-H  str. 3035 3090-3030 72
C=C str. 1512 1540-1480  ,,
1070 1125-1090  ,,
1028 1070-1000  ,,
Sulfonyl SO2 str. 1172 1185-1165  ,,
Amide NH-C=O str. 1668 1680-1636 71
Amine NH- str. 3325 3380-3350  ,,









Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range: 4000-400
cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.33 3 H singlet Ar-CH3 -
2 2.40 3 H singlet Ar-SO2 CH3 -
3 3.69-3.71 2 H doublet Ar-NH2 -
4 7.26-7.29 5 H multiplet Ar-H(c,g) -
5 7.65-7.68 2 H doublet Ar-Hb,b’             J=9.
6 7.74-7.77 2 H doublet Ar-Ha,a’             J=9




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz




























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 3 - A M I N O - 5 -
A RY LI D I N E - 2 - M E T H Y L - 2 - [ 4 - ( M E T H Y L S U L F O N Y L ) P H E N Y L ] - 1 , 3 -
THIAZOLIDIN-4-ONES
(A) Synthesis of 3-Amino-2-[4-(methylsulfonyl)phenyl]-1,3-thiazolidin-5-one
 To a solution of 1-[4-(methylsulfonyl)phenyl]ethanone hydrazone (2.12 gm,
0.01 mol) and mercaptoacetic acid (0.92 gm, 0.01 mol) in dry toluene(20ml) was
refluxed on heating mentle using  dean stark water separator for 10 hr. The reaction
mixture was cooled and excess toluene was distilled in vacuo. An oily liquid  was
obtained, which was poured  into hexene and kept overnight. The solid separated
was filtered and recrystlized from ethanol.Yield 48%; M.P. 168oC; Anal. Calcd. for
C11H14N2O3S2 Requires: C,46.13;  H,4.93;  N, 9.78 %; Found: C, 46.11; H, 4.92;
N, 9.76 %.
(B) Synthesis of 3- Amino- 4- benzylidine-2-methyl-2-[4-(methylsulfonyl)
phenyl]-1,3-thiazolidin-5-ones
To a solution of 3-amino-2-[4-(methylsulfonyl)phenyl]-1,3-thiazolidin-5-one
(2.54 gm, 0.01 mol) and benzaldehyde(1.06 gm, 0.01 mol) and anhydrous sodium
acetate(0.79 gm, 0.01 mol) in glacial acetic acid (20 ml) was refluxed on heating
mentle at 120oC for 12 hr. The reaction mixture was cooled and tritruted with 10%
sodiumsulphate solution. The product was crystallized from ethanol. Yield 48%;
M.P. 168oC; Anal. Calcd. for C18H18N2O3S2 Requires: C,57.73; H, 4.84; N, 7.48%;
Found: C, 57.71; H, 4.82; N, 7.49%.
Similarly other 3 - am i n o - 5 - ary lidine-2-methyl-2-[4-(methylsulfonyl)
phenyl]-1,3-thiazolidin-5-ones have been prepared the physical constants are
recorded in Table No. 13.
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(C) Biological screening of 3- Amino- 4- benzylidine-2-methyl-2-[4-
(methylsulfonyl)phenyl]-1,3-thiazolidin-5-ones
Antimicrobial testing were carried out as described in Part-I Section-1 (C).
The zones of inhibition of test solution are reported in Graphical Chart No 13.
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